Seven-Year Outcomes in Ranibizumab-Treated Patients

Ophthalmology
120, 2292-2299
DOI: 10.1016/j.ophtha.2013.03.046

Citation Report

#	Article	IF	Citations
4	Photodynamic therapy for polypoidal choroidal vasculopathy. Progress in Retinal and Eye Research, 2013, 37, 182-199.	7.3	82
5	Methallothionein-3 contributes to vascular endothelial growth factor induction in a mouse model of choroidal neovascularization. Metallomics, 2013, 5, 1387.	1.0	15
6	SRPK1 Inhibition Modulates VEGF Splicing to Reduce Pathological Neovascularization in a Rat Model of Retinopathy of Prematurity. , 2013, 54, 5797.		39
7	One-Year Outcome of Ranibizumab for Neovascular Age-Related Macular Degeneration: A Thorough Analysis in a Real-World Clinical Setting. European Journal of Ophthalmology, 2014, 24, 396-401.	0.7	22
8	A Delphi Study to Detect Deficiencies and Propose Actions in Real Life Treatment of Neovascular Age-Related Macular Degeneration. Journal of Ophthalmology, 2014, 2014, 1-10.	0.6	11
9	Current Treatment Limitations in Age-Related Macular Degeneration and Future Approaches Based on Cell Therapy and Tissue Engineering. Journal of Ophthalmology, 2014, 2014, 1-13.	0.6	53
10	Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration. Clinical Ophthalmology, 2014, 8, 717.	0.9	13
11	Interleukin-17 Induces Angiogenesis in Human Choroidal Endothelial Cells In Vitro. Investigative Ophthalmology and Visual Science, 2014, 55, 6968-6975.	3.3	30
12	Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degenerationâ€"the role of oral acetazolamide in protecting glaucoma patients. Eye, 2014, 28, 1218-1222.	1.1	23
13	Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography. British Journal of Ophthalmology, 2014, 98, 956-960.	2.1	27
14	Vascular Endothelial Growth Factor Antagonist Therapy for Retinopathy of Prematurity. Clinics in Perinatology, 2014, 41, 925-943.	0.8	52
15	IL-18 is not therapeutic for neovascular age-related macular degeneration. Nature Medicine, 2014, 20, 1372-1375.	15.2	37
16	Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain. BMC Ophthalmology, 2014, 14, 138.	0.6	6
17	EXACERBATION OF CHOROIDAL AND RETINAL PIGMENT EPITHELIAL ATROPHY AFTER ANTIâ€"VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2014, 34, 1308-1315.	1.0	67
18	Trends in Age-Related Macular Degeneration Management in Singapore. Optometry and Vision Science, 2014, 91, 872-877.	0.6	13
19	Long-term longitudinal study of patients treated with ranibizumab for neovascular age-related macular degeneration. Current Opinion in Ophthalmology, 2014, 25, 158-163.	1.3	30
21	Partial and Transient Reduction of Glycolysis by PFKFB3 Blockade Reduces Pathological Angiogenesis. Cell Metabolism, 2014, 19, 37-48.	7.2	429
22	Current Strategies for the Management of Treatment-Resistant Neovascular Age-Related Macular Degeneration. Current Ophthalmology Reports, 2014, 2, 6-13.	0.5	5

#	Article	IF	Citations
23	Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGFâ€A levels. FASEB Journal, 2014, 28, 2369-2379.	0.2	48
24	The Photosynthetic Eukaryote Nannochloris eukaryotum as an Intracellular Machine To Control and Expand Functionality of Human Cells. Nano Letters, 2014, 14, 2720-2725.	4.5	8
25	Glycobiology of ocular angiogenesis. Glycobiology, 2014, 24, 1275-1282.	1.3	12
26	Genistein attenuates choroidal neovascularization. Journal of Nutritional Biochemistry, 2014, 25, 1177-1182.	1.9	9
27	A safety evaluation of ranibizumab in the treatment of age-related macular degeneration. Expert Opinion on Drug Safety, 2014, 13, 1259-1270.	1.0	13
28	Vasoprotective effect of PDGF-CC mediated by HMOX1 rescues retinal degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14806-14811.	3.3	24
29	Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. The Cochrane Library, 2014, , CD005139.	1.5	255
30	Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 1705-1709.	1.0	68
31	Doxycycline Inhibits Polarization of Macrophages to the Proangiogenic M2-type and Subsequent Neovascularization. Journal of Biological Chemistry, 2014, 289, 8019-8028.	1.6	71
32	Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). British Journal of Ophthalmology, 2014, 98, 1144-1167.	2.1	463
33	The role of proteases and inflammatory molecules in triggering neovascular age-related macular degeneration: basic science to clinical relevance. Translational Research, 2014, 164, 179-192.	2.2	10
34	Driving Habits in Older Patients with Central Vision Loss. Ophthalmology, 2014, 121, 727-732.	2.5	44
35	Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen. British Journal of Ophthalmology, 2014, 98, 1197-1200.	2.1	15
36	Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid. Saudi Journal of Ophthalmology, 2014, 28, 129-133.	0.3	24
37	Evaluation of Choroidal Neovascularization With Indocyanine Green Angiography in Neovascular Age-Related Macular Degeneration Subjects Undergoing Intravitreal Bevacizumab Therapy. American Journal of Ophthalmology, 2014, 158, 337-344.	1.7	20
38	A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. British Journal of Ophthalmology, 2014, 98, i22-i27.	2.1	64
39	Treatment of Exudative Age-Related Macular Degeneration with a Designed Ankyrin Repeat Protein that Binds Vascular Endothelial Growth Factor: a Phase I/II Study. American Journal of Ophthalmology, 2014, 158, 724-732.e2.	1.7	70
40	Anti-VEGF Treatment Patterns for Neovascular Age-Related Macular Degeneration Among Medicare Beneficiaries. American Journal of Ophthalmology, 2014, 158, 537-543.e2.	1.7	55

#	Article	IF	Citations
41	Neuropilin-1 enforces extracellular matrix signalling via ABL1 to promote angiogenesis. Biochemical Society Transactions, 2014, 42, 1429-1434.	1.6	18
42	Effect of Switching Therapy to Pegaptanib in Eyes With the Persistent Cases of Exudative Age-Related Macular Degeneration. Medicine (United States), 2014, 93, e116.	0.4	10
43	Stereotactic low voltage x-ray radiotherapy for treating neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2014, 9, 153-158.	0.3	0
44	Diffusion of anti-VEGF injections in the Portuguese National Health System. BMJ Open, 2015, 5, e009006.	0.8	10
45	Bestâ€corrected visual acuity and retinal thickness are associated with improved cortical visual processing in treated wet <scp>AMD</scp> patients. Acta Ophthalmologica, 2015, 93, 621-625.	0.6	8
46	What Does Genetics Tell Us About Age-Related Macular Degeneration?. Annual Review of Vision Science, 2015, 1, 73-96.	2.3	21
47	INCIDENCE OF OUTER RETINAL TUBULATION IN RANIBIZUMAB-TREATED AGE-RELATED MACULAR DEGENERATION. Retina, 2015, 35, 1166-1172.	1.0	16
48	MULTIMODAL IMAGING FINDINGS AND MULTIMODAL VISION TESTING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2015, 35, 1292-1302.	1.0	26
49	ARE INTRAVITREAL INJECTIONS WITH ULTRATHIN 33-G NEEDLES LESS PAINFUL THAN THE COMMONLY USED 30-G NEEDLES?. Retina, 2015, 35, 1778-1785.	1.0	26
50	TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH RANIBIZUMAB COMBINED WITH KETOROLAC EYEDROPS OR PHOTODYNAMIC THERAPY. Retina, 2015, 35, 1547-1554.	1.0	15
51	A Decade of Anti-VEGF Drugs in Ophthalmology- Successes and Challenges. Journal of Clinical & Experimental Ophthalmology, 2015, 06, .	0.1	1
52	Restoration of Outer Retinal Layers After Aflibercept Therapy in Exudative AMD: Prognostic Value. , 2015, 56, 4129.		37
53	A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis. Clinical Ophthalmology, 2015, 9, 1759.	0.9	28
54	The role of aflibercept in the management of diabetic macular edema. Drug Design, Development and Therapy, 2015, 9, 4389.	2.0	10
55	Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration. Journal of Clinical Medicine, 2015, 4, 1380-1402.	1.0	56
56	Suppression of Laser-Induced Choroidal Neovascularization by the Oral Medicine Targeting Histamine Receptor H4 in Mice. Translational Vision Science and Technology, 2015, 4, 6.	1.1	14
57	Baseline Predictors for Good Versus Poor Visual Outcomes in the Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Therapy. , 2015, 56, 5040.		46
58	Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development. Clinical Ophthalmology, 2015, 9, 1001.	0.9	35

#	Article	IF	Citations
59	The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study. PLoS ONE, 2015, 10, e0133628.	1.1	31
60	Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections. Journal of Ophthalmology, 2015, 2015, 1-5.	0.6	8
61	Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration. Journal of Ophthalmology, 2015, 2015, 1-8.	0.6	16
62	Strategies for improving early detection and diagnosis of neovascular age-related macular degeneration. Clinical Ophthalmology, 2015, 9, 353.	0.9	42
63	IL-18 Immunotherapy for Neovascular AMD: Tolerability and Efficacy in Nonhuman Primates. , 2015, 56, 5424.		31
65	The genetics of age-related macular degeneration (AMD) â€“ Novel targets for designing treatment options?. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 194-202.	2.0	33
66	Long-Term Outcomes in Eyes Receiving Fixed-Interval Dosing of Antiâ€“Vascular Endothelial Growth Factor Agents for Wet Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 803-808.	2.5	112
67	Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: â€œreal lifeâ€•long-term outcome. BMC Ophthalmology, 2015, 15, 39.	0.6	9
68	Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. BMC Ophthalmology, 2015, 15, 40.	0.6	23
69	Imatinib may be ABL to improve anti-angiogenic therapy. Molecular and Cellular Oncology, 2015, 2, e968034.	0.3	3
70	UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12. British Journal of Ophthalmology, 2015, 99, 1045-1050.	2.1	51
71	DÃ©gÃ©nÃ©rescence maculaire liÃ©e Ã lâ€™Ã¢ge. Ã‰tat des lieux 2015. Revue Francophone D'Orthoptie, 2015, 8, 118-135.	0.0	1
72	Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability. American Journal of Pathology, 2015, 185, 2534-2549.	1.9	24
73	Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom. Eye, 2015, 29, 403-408.	1.1	19
74	Clinical characteristics and outcomes after 5Âyears pro re nata treatment of neovascular ageâ€•related macular degeneration with ranibizumab. Acta Ophthalmologica, 2015, 93, e511-2.	0.6	8
75	Gene- and Cell-Based Treatment Strategies for the Eye. Essentials in Ophthalmology, 2015, , .	0.0	2
76	ROCK-Isoform-Specific Polarization of Macrophages Associated with Age-Related Macular Degeneration. Cell Reports, 2015, 10, 1173-1186.	2.9	154
77	Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab. Japanese Journal of Ophthalmology, 2015, 59, 36-42.	0.9	25

#	Article	IF	Citations
78	Antibody therapies and their challenges in the treatment of age-related macular degeneration. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 158-172.	2.0	54
79	Individualizing the intravitreal anti-VEGF dosing regimen for long-term management of neovascular AMD. Ophthalmic Surgery Lasers and Imaging Retina, 2015, 46, 508-512.	0.4	7
80	Increased Fundus Autofluorescence and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GAIN Study. American Journal of Ophthalmology, 2015, 160, 345-353.e5.	1.7	49
81	Long-Term Outcomes of Treatment ofÂNeovascular Age-Related MacularÂDegeneration. Ophthalmology, 2015, 122, 1837-1845.	2.5	206
82	Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. British Journal of Ophthalmology, 2015, 99, 220-226.	2.1	474
83	Advances in pharmacotherapy for wet age-related macular degeneration. Expert Opinion on Pharmacotherapy, 2015, 16, 1769-1781.	0.9	27
84	Stem cell based therapies for age-related macular degeneration: The promises and the challenges. Progress in Retinal and Eye Research, 2015, 48, 1-39.	7.3	167
85	Macular Atrophy Progression and 7-Year Vision Outcomes in Subjects From the ANCHOR, MARINA, and HORIZON Studies: the SEVEN-UP Studyâˆ—. American Journal of Ophthalmology, 2015, 159, 915-924.e2.	1.7	168
86	Long-Term Results of Full Macular Translocation for Choroidal Neovascularization in Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 1366-1374.	2.5	21
89	Long-term outcome of intravitreal pegaptanib sodium as maintenance therapy in Japanese patients with neovascular age-related macular degeneration. Japanese Journal of Ophthalmology, 2015, 59, 173-178.	0.9	5
90	Defining response to anti-VEGF therapies in neovascular AMD. Eye, 2015, 29, 721-731.	1.1	214
91	Emerging Therapeutic Options in Age-Related Macular Degeneration. Ophthalmic Research, 2015, 53, 194-199.	1.0	10
92	Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy. BMC Ophthalmology, 2015, 15, 37.	0.6	7
93	Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel. Eye, 2015, 29, S1-S11.	1.1	22
95	Ranibizumab Treatment for Retinal Angiomatous Proliferation Lesions: A Case Report with Life-Long Expectancy (Seven Years) Follow-Up. Klinische Monatsblatter Fur Augenheilkunde, 2015, 232, 570-572.	0.3	0
96	Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet, The, 2015, 386, 2395-2403.	6.3	154
98	Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. Angiogenesis, 2015, 18, 397-432.	3.7	31
99	Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth FactorÂTreatment. Ophthalmology, 2015, 122, 2303-2310.	2.5	92

#	Article	IF	Citations
100	Parainflammation, chronic inflammation, and age-related macular degeneration. Journal of Leukocyte Biology, 2015, 98, 713-725.	1.5	256
101	Response-based individualized medicine for neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2015, 10, 105-112.	0.3	2
102	Peripapillary RNFL thickness in nonexudative versus chronically treated exudative age-related macular degeneration. Canadian Journal of Ophthalmology, 2015, 50, 345-349.	0.4	9
103	Reevaluating the Definition of Intraretinal Microvascular Abnormalities and Neovascularization Elsewhere in Diabetic Retinopathy Using Optical Coherence Tomography and Fluorescein Angiography. American Journal of Ophthalmology, 2015, 159, 101-110.e1.	1.7	73
104	AAV2 Delivery of Flt23k Intraceptors Inhibits Murine Choroidal Neovascularization. Molecular Therapy, 2015, 23, 226-234.	3.7	21
105	Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye. Trends in Molecular Medicine, 2015, 21, 43-51.	3.5	107
106	Vision-Threatening Lesions Developing with Longer-Term Follow-up after Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2015, 122, 153-161.	2.5	26
107	Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes. Clinical Ophthalmology, 2016, 10, 313.	0.9	12
108	The Intraocular Cytokine Profile and Therapeutic Response in Persistent Neovascular Age-Related Macular Degeneration. , 2016, 57, 4144.		64
109	Intravitreal Anti-Vascular Endothelial Growth Factor for Retinal Pigment Epithelial Tear in Retinal Angiomatous Proliferation. Journal of Korean Ophthalmological Society, 2016, 57, 71.	0.0	2
110	Beyond VEGFâ€"The Weisenfeld Lecture. , 2016, 57, 6911.		49
111	Intravitreal Antiâ€"Vascular Endothelial Growth Factor Therapy and Retinal Nerve Fiber Layer Loss in Eyes With Age-Related Macular Degeneration: A Meta-Analysis. , 2016, 57, 1798.		40
112	Stemming the Tide of Age-Related Macular Degeneration: New Therapies for Old Retinas. , 2016, 57, ORSFb1.		7
113	Geographic Atrophy and Activity of Neovascularization in Retinal Angiomatous Proliferation. , 2016, 57, 1500.		28
114	OCT Angiographyâ€"Based Detection and Quantification of the Neovascular Network in Exudative AMD. , 2016, 57, 6342.		33
115	Different Ipsi- and Contralateral Glial Responses to Anti-VEGF and Triamcinolone Intravitreal Injections in Rats. , 2016, 57, 3533.		27
116	Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up. Clinical Ophthalmology, 2016, 10, 1047.	0.9	4
117	Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment. Clinical Ophthalmology, 2016, Volume 10, 2505-2513.	0.9	4

#	Article	IF	Citations
118	C3a Increases VEGF and Decreases PEDF mRNA Levels in Human Retinal Pigment Epithelial Cells. BioMed Research International, 2016, 2016, 1-7.	0.9	27
119	Effects of Intravitreal Ranibizumab Injection on Chinese Patients with Wet Age-Related Macular Degeneration: 5-Year Follow-Up Results. Journal of Ophthalmology, 2016, 2016, 1-5.	0.6	4
120	Biomaterials for intraocular sustained drug delivery. , 2016, , 131-147.		0
121	Fucoidan as a Potential Therapeutic for Major Blinding Diseasesâ€"A Hypothesis. Marine Drugs, 2016, 14, 31.	2.2	33
122	Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Design, Development and Therapy, 2016, 10, 1857.	2.0	164
123	AFLIBERCEPT FOR THE TREATMENT OF RETINAL PIGMENT EPITHELIAL DETACHMENTS. Retina, 2016, 36, 492-498.	1.0	22
124	INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY. Retina, 2016, 36, 770-777.	1.0	26
125	INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. Retina, 2016, 36, 859-867.	1.0	48
126	Distal retinal ganglion cell axon transport loss and activation of p38 MAPK stress pathway following VEGF-A antagonism. Cell Death and Disease, 2016, 7, e2212-e2212.	2.7	25
127	Characterizing relationship between optical microangiography signals and capillary flow using microfluidic channels. Biomedical Optics Express, 2016, 7, 2709.	1.5	48
128	SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT. Retina, 2016, 36, 1126-1131.	1.0	39
129	Interleukinâ€17A neutralization alleviated ocular neovascularization by promoting M2 and mitigating M1 macrophage polarization. Immunology, 2016, 147, 414-428.	2.0	45
130	Extended release anti-VEGF systems: a strategy whose time has come? Or already gone?. Expert Review of Ophthalmology, 2016, 11, 167-169.	0.3	0
132	Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. British Journal of Ophthalmology, 2017, 101, bjophthalmol-2016-308668.	2.1	120
133	UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92â€...976 intravitreal ranibizumab injections. British Journal of Ophthalmology, 2016, 100, 1617-1622.	2.1	17
134	Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy. British Journal of Ophthalmology, 2016, 100, 1611-1616.	2.1	7
135	Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. British Journal of Ophthalmology, 2016, 100, 1640-1645.	2.1	36
136	Changing from apro re natatreatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. British Journal of Ophthalmology, 2016, 100, 1341-1345.	2.1	43

#	Article	IF	Citations
137	Sustained intraocular VEGF neutralization results in retinal neurodegeneration in the Ins2Akita diabetic mouse. Scientific Reports, 2016, 5, 18316.	1.6	54
138	Increased <scp>VEGF</scp> â€A promotes multiple distinct aging diseases of the eye through shared pathomechanisms. EMBO Molecular Medicine, 2016, 8, 208-231.	3.3	42
139	VISUALIZING RETINAL PIGMENT EPITHELIUM PHENOTYPES IN THE TRANSITION TO ATROPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2016, 36, S26-S39.	1.0	55
140	Interferonâ€beta signaling in retinal mononuclear phagocytes attenuates pathological neovascularization. EMBO Molecular Medicine, 2016, 8, 670-678.	3.3	68
141	Wide-field optical coherence tomography based microangiography for retinal imaging. Scientific Reports, 2016, 6, 22017.	1.6	110
142	METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2016, 36, 1418-1431.	1.0	145
143	Age-related macular degeneration. British Journal of Hospital Medicine (London, England: 2005), 2016, 77, C18-C21.	0.2	8
144	Burning fat fuels photoreceptors. Nature Medicine, 2016, 22, 342-343.	15.2	12
145	Patient iPSCs: a new discovery tool for Smith-Lemli-Opitz syndrome. Nature Medicine, 2016, 22, 343-344.	15.2	2
146	A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo. Journal of Controlled Release, 2016, 233, 198-207.	4.8	25
147	Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Progress in Retinal and Eye Research, 2016, 53, 107-139.	7.3	276
148	Neutralization of IL-23 depresses experimental ocular neovascularization. Experimental Eye Research, 2016, 146, 242-251.	1.2	14
149	Retinal Ganglion Cell Layer Change in Patients Treated With Antiâ€"Vascular Endothelial Growth Factor for Neovascular Age-related Macular Degeneration. American Journal of Ophthalmology, 2016, 167, 10-17.	1.7	64
150	Long-Term Outcomes of Anti-Vascular Endothelial Growth Factor Therapy for Polypoidal Choroidal Vasculopathy. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 219-224.	0.6	12
151	Pharmacology of the retinal pigment epithelium, the interface between retina and body system. European Journal of Pharmacology, 2016, 787, 84-93.	1.7	29
152	Manual of Retinal Diseases. , 2016, , .		3
153	Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts. Advances in Therapy, 2016, 33, 715-726.	1.3	11
154	Retinal Vascular Occlusions: Review of Clinical Trials. , 2016, , 311-314.		0

#	Article	IF	Citations
155	Five-Year Outcomes with Antiâ€"Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmology, 2016, 123, 1751-1761.	2.5	541
156	Long-term Results of Intravitreal Anti-VEGF Injections in Wet AMD: A Meta-Analysis. Klinische Monatsblatter Fur Augenheilkunde, 2016, 233, 471-474.	0.3	18
158	Anti-vascular Endothelial Growth Factor (VEGF) Treatment in Neovascular Age-Related Macular Degeneration: Outcomes and Outcome Predictors. Essentials in Ophthalmology, 2016, , 31-65.	0.0	0
159	Method development to quantify Bv8 expression in circulating CD11b+ cells in patients with neovascular age-related macular degeneration (nvAMD) exhibiting Anti-VEGF refractoriness. Experimental Eye Research, 2016, 148, 45-51.	1.2	4
160	UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV. Ophthalmology, 2016, 123, 2386-2392.	2.5	31
161	Tenascin-C secreted by transdifferentiated retinal pigment epithelial cells promotes choroidal neovascularization via integrin Î±V. Laboratory Investigation, 2016, 96, 1178-1188.	1.7	27
163	On the Use of Photodynamic Therapy, as Monotherapy or in Combination, in the Treatment of Polypoidal Choroidal Vasculopathy: An Update. , 2016, , 421-435.		1
164	A Revised Hemodynamic Theory of Age-Related Macular Degeneration. Trends in Molecular Medicine, 2016, 22, 656-670.	3.5	45
165	Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye, 2016, 30, 1531-1541.	1.1	17
166	Real world evidence of use of anti-VEGF therapy in Denmark. Current Medical Research and Opinion, 2016, 32, 1943-1950.	0.9	22
168	Role of Omega-3 Fatty Acids for Eye Health. , 2016, , 251-261.		0
169	Macular atrophy in patients with longâ€term antiâ€VEGF treatment for neovascular ageâ€related macular degeneration. Acta Ophthalmologica, 2016, 94, e757-e764.	0.6	85
170	Licence to save: a UK survey of anti-VEGF use for the eye in 2015. Eye, 2016, 30, 1404-1406.	1.1	22
171	Big Data and Uveitis. Ophthalmology, 2016, 123, 2273-2275.	2.5	18
172	Retinal pigment epithelial atrophy over polypoidal choroidal vasculopathy lesions during ranibizumab monotherapy. BMC Ophthalmology, 2016, 16, 55.	0.6	7
173	GEOGRAPHIC ATROPHY. Retina, 2016, 36, 2250-2264.	1.0	57
174	TREAT-AND-EXTEND REGIMEN WITH AFLIBERCEPT FOR RETINAL ANGIOMATOUS PROLIFERATION. Retina, 2016, 36, 2282-2289.	1.0	33
175	Stereotactic radiotherapy in neovascular age-related macular degeneration. Medicine (United States), 2016, 95, e5729.	0.4	16

#	Article	IF	Citations
176	Association of Anti-VEGF Injections with Progression of Geographic Atrophy. Ophthalmology and Eye Diseases, 2016, 8, OED.S38863.	1.2	23
177	The concept of virtual clinics in monitoring patients with ageâ€related macular degeneration. Acta Ophthalmologica, 2016, 94, e353-5.	0.6	35
178	Prognostic implications of imaging in atrophic macular degeneration and its use in clinical practice and clinical trial design. Clinical and Experimental Ophthalmology, 2016, 44, 410-421.	1.3	2
179	Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration. American Journal of Ophthalmology, 2016, 169, 95-103.	1.7	24
180	Targeting Platelet-Derived Growth Factor Receptor Î²+ Scaffold Formation Inhibits Choroidal Neovascularization. American Journal of Pathology, 2016, 186, 1890-1899.	1.9	28
182	Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration. American Journal of Ophthalmology, 2016, 168, 1-12.	1.7	92
183	Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration. Experimental Eye Research, 2016, 145, 248-257.	1.2	17
184	Targeting VEGF in eye neovascularization: What's new?. Pharmacological Research, 2016, 103, 253-269.	3.1	137
185	Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA,Âand HORIZON (SEVEN-UP Study). Ophthalmology, 2016, 123, 1269-1277.	2.5	67
186	Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis. Journal of Biological Chemistry, 2016, 291, 7242-7255.	1.6	36
187	Economic and Quality of Life Benefits of Anti-VEGF Therapy. Molecular Pharmaceutics, 2016, 13, 2877-2880.	2.3	20
188	Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration. Ophthalmologica, 2016, 235, 42-48.	1.0	19
189	Malondialdehyde induces autophagy dysfunction and VEGF secretion in the retinal pigment epithelium in age-related macular degeneration. Free Radical Biology and Medicine, 2016, 94, 121-134.	1.3	50
190	NRP1 function and targeting in neurovascular development and eye disease. Progress in Retinal and Eye Research, 2016, 52, 64-83.	7.3	63
191	Treatment for neovascular age related macular degeneration: The state of the art. European Journal of Pharmacology, 2016, 787, 78-83.	1.7	21
192	Retinal Pigment Epithelial Atrophy in Neovascular Age-Related Macular Degeneration After Ranibizumab Treatment. American Journal of Ophthalmology, 2016, 161, 94-103.e1.	1.7	36
193	The design and implementation of a study to investigate the effectiveness of community vs hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease. Eye, 2016, 30, 68-78.	1.1	3
194	VEGF-A and the NLRP3 Inflammasome in Age-Related Macular Degeneration. Advances in Experimental Medicine and Biology, 2016, 854, 79-85.	0.8	16

#	Article	IF	Citations
195	Long-term outcomes of intravitreal ranibizumab for neovascular age-related macular degeneration in a well defined region of the UK. British Journal of Ophthalmology, 2016, 100, 240-245.	2.1	13
196	A 24-Month Evaluation of Aflibercept for Wet Age-Related Macular Degeneration in Patients Previously Receiving Ranibizumab or Bevacizumab. Ophthalmology Retina, 2017, 1, 111-117.	1.2	1
197	Risk of Posterior Capsule Rupture During Cataract Surgery in Eyes With Previous Intravitreal Injections. American Journal of Ophthalmology, 2017, 177, 77-80.	1.7	28
198	MicroRNA-processing Enzymes Are Essential for Survival and Function of Mature Retinal Pigmented Epithelial Cells in Mice. Journal of Biological Chemistry, 2017, 292, 3366-3378.	1.6	22
199	Fundus autofluorescence imaging: systematic review of test accuracy for the diagnosis and monitoring of retinal conditions. Eye, 2017, 31, 995-1007.	1.1	22
200	Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment. Molecular Therapy, 2017, 25, 1606-1615.	3.7	12
201	The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited. International Journal of Retina and Vitreous, 2017, 3, 5.	0.9	11
202	Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 963-972.	1.0	41
203	Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections. Cutaneous and Ocular Toxicology, 2017, 36, 343-346.	0.5	35
204	Sema3f Protects Against Subretinal Neovascularization In Vivo. EBioMedicine, 2017, 18, 281-287.	2.7	20
205	Special Commentary: Early Clinical Development of Cell Replacement Therapy: Considerations for the National Eye Institute Audacious Goals Initiative. Ophthalmology, 2017, 124, 926-934.	2.5	10
206	RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2017, 37, 2035-2046.	1.0	13
207	Choroidal Thickness and Visual Prognosis in Type 1 Lesion Due to Neovascular Age-Related Macular Degeneration. European Journal of Ophthalmology, 2017, 27, 196-200.	0.7	5
208	Advances in Vision Research, Volume I. Essentials in Ophthalmology, 2017, , .	0.0	0
209	ROLE OF ADDITIONAL DEXAMETHASONE FOR THE MANAGEMENT OF PERSISTENT OR RECURRENT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDER RANIBIZUMAB TREATMENT. Retina, 2017, 37, 962-970.	1.0	17
210	Autologous Bone Marrow-Derived Cell Therapies for Retinal Disease. , 2017, , 79-94.		0
211	Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial. American Journal of Ophthalmology, 2017, 180, 142-150.	1.7	64
212	Decreased Visual Function Scores on a Low Luminance Questionnaire Is Associated with Impaired Dark Adaptation. Ophthalmology, 2017, 124, 1332-1339.	2.5	23

#	Article	IF	Citations
213	Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal antiâ€"vascular endothelial growth factor therapy of macular diseases. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1259-1273.	1.0	113
214	Vitamin D receptor agonists regulate ocular developmental angiogenesis and modulate expression of dreâ€miRâ€21 and VEGF. British Journal of Pharmacology, 2017, 174, 2636-2651.	2.7	37
215	LONG-TERM OUTCOMES AND INCIDENCE OF RECURRENCE OF NEOVASCULARIZATION IN TREATED EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2017, 37, 951-961.	1.0	22
216	On phagocytes and macular degeneration. Progress in Retinal and Eye Research, 2017, 61, 98-128.	7.3	121
217	Economic Evaluation of a Home-Based Age-Related Macular Degeneration Monitoring System. JAMA Ophthalmology, 2017, 135, 452.	1.4	38
219	One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration. Ophthalmologica, 2017, 237, 139-144.	1.0	24
220	Autologous Induced Stem-Cellâ€"Derived Retinal Cells for Macular Degeneration. New England Journal of Medicine, 2017, 376, 1038-1046.	13.9	1,121
221	Autophagy and KRT8/keratin 8 protect degeneration of retinal pigment epithelium under oxidative stress. Autophagy, 2017, 13, 248-263.	4.3	55
222	Polysialic acid blocks mononuclear phagocyte reactivity, inhibits complement activation, and protects from vascular damage in the retina. EMBO Molecular Medicine, 2017, 9, 154-166.	3.3	63
223	Proteolytic Degradation and Inflammation Play Critical Roles in Polypoidal Choroidal Vasculopathy. American Journal of Pathology, 2017, 187, 2841-2857.	1.9	27
224	Comparison of Strategies of Treatment with Ranibizumab in Newly-Diagnosed Cases of Neovascular Age-Related Macular Degeneration. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 773-778.	0.6	10
225	Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Ophthalmologica, 2017, 238, 217-225.	1.0	13
226	High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases. Journal of Controlled Release, 2017, 266, 301-309.	4.8	34
227	Treatment for neovascular ageâ€related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register. Acta Ophthalmologica, 2017, 95, 787-795.	0.6	29
228	Cell Therapy for Ophthalmic Diseases. Molecular and Translational Medicine, 2017, , 249-279.	0.4	1
229	A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration. Scientific Reports, 2017, 7, 9196.	1.6	24
230	An 8â€year followâ€up of antiâ€vascular endothelial growth factor treatment with a treatâ€andâ€extend modality for neovascular ageâ€related macular degeneration. Acta Ophthalmologica, 2017, 95, 796-802.	0.6	64
231	Changes in Peripapillary Nerve Fiber Layer Thickness after Adjuvant Stereotactic Radiotherapy in Patients with Neovascular Age-Related Macular Degeneration. Current Eye Research, 2017, 42, 1698-1706.	0.7	1

#	Article	IF	Citations
232	2016 Glenn A. Fry Award Lecture: Mechanisms and Potential Treatments of Early Age-Related Macular Degeneration. Optometry and Vision Science, 2017, 94, 939-945.	0.6	2
233	Phase I Trial of Antiâ€"Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2017, 1, 474-485.	1.2	63
234	Age-related macular degeneration: is polypoidal choroidal vasculopathy recognized and treated?. Canadian Journal of Ophthalmology, 2017, 52, 475-479.	0.4	5
235	A Proinflammatory Function of Toll-Like Receptor 2 in the Retinal Pigment Epithelium as a Novel Target for Reducing Choroidal Neovascularization in Age-Related Macular Degeneration. American Journal of Pathology, 2017, 187, 2208-2221.	1.9	27
236	ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 2091-2098.	1.0	11
237	A genome-wide association study identified a novel genetic loci STON1-GTF2A1L/LHCGR/FSHR for bilaterality of neovascular age-related macular degeneration. Scientific Reports, 2017, 7, 7173.	1.6	8
238	RISK FACTORS AND CLINICAL SIGNIFICANCE OF PRECHOROIDAL CLEFT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2017, 37, 2047-2055.	1.0	15
239	Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration. Medicine (United States), 2017, 96, e6422.	0.4	6
240	Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development. Expert Opinion on Investigational Drugs, 2017, 26, 1103-1114.	1.9	16
241	Pluripotent stem cells and their utility in treating photoreceptor degenerations. Progress in Brain Research, 2017, 231, 191-223.	0.9	19
242	Hot Topics in Pharmacotherapy for Neovascular Age-Related Macular Degeneration. Current Pharmaceutical Design, 2017, 23, 535-541.	0.9	7
243	Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1891-1897.	1.0	58
244	Identification of different macrophage subpopulations with distinct activities in a mouse model of oxygen-induced retinopathy. International Journal of Molecular Medicine, 2017, 40, 281-292.	1.8	48
245	Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology, 2017, 124, 97-104.	2.5	158
246	Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration. Japanese Journal of Ophthalmology, 2017, 61, 74-83.	0.9	16
247	Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. Eye, 2017, 31, 1-9.	1.1	87
248	New Treatment Modalities for Neovascular Age-Related Macular Degeneration. Asia-Pacific Journal of Ophthalmology, 2017, 6, 514-519.	1.3	23
249	Anti-VEGF Therapy for Neovascular AMD and Polypoidal Choroidal Vasculopathy. Asia-Pacific Journal of Ophthalmology, 2017, 6, 527-534.	1.3	29

#	Article	IF	Citations
250	Recent developments in age-related macular degeneration: a review. Clinical Interventions in Aging, 2017, Volume 12, 1313-1330.	1.3	285
251	Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning. Clinical Ophthalmology, 2017, Volume 11, 809-816.	0.9	10
252	Effects of bevacizumab on endoplasmic reticulum stress in hypoxic retinal pigment epithelial cells. PLoS ONE, 2017, 12, e0179048.	1.1	6
253	Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab. BMC Ophthalmology, 2017, 17, 147.	0.6	12
254	Investigation of time to first presentation and extrahospital factors in the treatment of neovascular age-related macular degeneration: a retrospective cross-sectional study. BMJ Open, 2017, 7, e017771.	0.8	13
255	The Implantable Miniature Telescope and Quality of Life Improvements in Patients with End-Stage Age-Related Macular Degeneration. , 2017, 07, .		2
256	Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience. Korean Journal of Ophthalmology: KJO, 2017, 31, 424.	0.5	11
257	New molecular targets for the treatment of neovascular age-related macular degeneration. Translational Medicine Reports, 2017, 1, .	0.8	0
258	Neovascular (Wet) Age-Related Macular Degeneration. , 2017, , 89-116.		3
259	CD11b and CD200 on Circulating Monocytes Differentiate Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy. , 2017, 58, 5242.		19
260	MicroRNA-370 suppresses the retinal capillary endothelial cell growth by targeting KDR gene. Bratislava Medical Journal, 2017, 118, 202-207.	0.4	7
261	Galectin-3 Inhibition by a Small-Molecule Inhibitor Reduces Both Pathological Corneal Neovascularization and Fibrosis. , 2017, 58, 9.		55
262	Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration. , 2017, 58, 6038.		11
263	Advances in Age-related Macular Degeneration Understanding and Therapy. US Ophthalmic Review, 2017, 10, 119.	0.2	53
264	Autophagy activated by SIRT6 regulates AÎ² induced inflammatory response in RPEs. Biochemical and Biophysical Research Communications, 2018, 496, 1148-1154.	1.0	16
265	The fate of eyes with wet AMD beyond four years of anti-VEGF therapy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 823-831.	1.0	22
266	Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration. Survey of Ophthalmology, 2018, 63, 638-645.	1.7	41
267	Human aging and disease: Lessons from age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2866-2872.	3.3	59

#	Article	IF	Citations
268	Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium. Experimental Eye Research, 2018, 171, 1-11.	1.2	12
269	Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2018, 125, 878-886.	2.5	101
270	Antiâ€vascular endothelial growth factors treatment of wet ageâ€related macular degeneration: from neurophysiology to costâ€effectiveness. Acta Ophthalmologica, 2018, 96, 1-46.	0.6	2
271	Inhibition of integrin Î±5Î²1 ameliorates VEGF-induced retinal neovascularization and leakage by suppressing NLRP3 inflammasome signaling in a mouse model. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 951-961.	1.0	15
272	Choroidal pericytes promote subretinal fibrosis after experimental photocoagulation. DMM Disease Models and Mechanisms, 2018, 11, .	1.2	19
273	Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology, 2018, 125, 1037-1046.	2.5	60
274	Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Antiâ€"VEGF Injections Using a Treat-Extend-Stop Protocol. Ophthalmology, 2018, 125, 1047-1053.	2.5	59
275	Treat-and-Extend Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2018, 2, 462-468.	1.2	26
276	Long-Term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Antiâ€"Vascular Endothelial Growth Factor. Ophthalmology Retina, 2018, 2, 550-557.	1.2	12
277	AAV-mediated gene delivery of the calreticulin anti-angiogenic domain inhibits ocular neovascularization. Angiogenesis, 2018, 21, 95-109.	3.7	19
278	A 5-year multicenter prospective cohort study on the long-term visual prognosis and predictive factors for visual outcome in Japanese patients with age-related macular degeneration: the AMD2000 study. Japanese Journal of Ophthalmology, 2018, 62, 137-143.	0.9	4
279	Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors. Progress in Retinal and Eye Research, 2018, 65, 127-146.	7.3	205
280	Combined VEGF/PDGF inhibition using axitinib induces Î±SMA expression and a pro-fibrotic phenotype in human pericytes. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 1141-1149.	1.0	14
281	INTRAVITREAL AFLIBERCEPT INJECTION FOR CHOROIDAL NEOVASCULARIZATION DUE TO PRESUMED OCULAR HISTOPLASMOSIS SYNDROME. Retina, 2018, 38, 755-763.	1.0	10
282	WRINKLED VASCULARIZED RETINAL PIGMENT EPITHELIUM DETACHMENT PROGNOSIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina, 2018, 38, 1100-1109.	1.0	9
283	Aquaporins: Novel Targets for Age-Related Ocular Disorders. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 177-187.	0.6	10
284	TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN EVERYDAY PRACTICE. Retina, 2018, 38, 1134-1144.	1.0	17
285	OUTCOMES OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR THREE OR MORE YEARS. Retina, 2018, 38, 1500-1508.	1.0	23

#	Article	IF	Citations
286	PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTIâ€"VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina, 2018, 38, 1276-1288.	1.0	45
287	Reply to: â€˜Comment on: â€˜One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degenerationâ€™. Eye, 2018, 32, 479-481.	1.1	0
288	Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data. British Journal of Ophthalmology, 2018, 102, 465-472.	2.1	10
289	INTRAVITREAL INJECTION OF AFLIBERCEPT IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2018, 38, 2001-2009.	1.0	18
290	Clinical and social characteristics associated with reduced visual acuity at presentation in Australian patients with neovascular ageâ€related macular degeneration: a prospective study from a longâ€term observational data set. The Fight Retinal Blindness! Project. Clinical and Experimental Ophthalmology, 2018, 46, 266-274.	1.3	4
291	Recurrence Rate of Choroidal Neovascularization in Neovascular Age-Related Macular Degeneration ManagedÂwith a Treatâ€"Extendâ€"Stop Protocol. Ophthalmology Retina, 2018, 2, 225-230.	1.2	45
292	Potential selection bias in candidates for stereotactic radiotherapy for neovascular AMD. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 105-111.	1.0	2
293	Treatâ€andâ€extend versus everyâ€otherâ€month regimens with aflibercept in ageâ€related macular degeneration. Acta Ophthalmologica, 2018, 96, e393-e398.	0.6	33
294	Baseline Predictors for Five-Year Visual Acuity Outcomes in the Comparison of AMD Treatment Trials. Ophthalmology Retina, 2018, 2, 525-530.	1.2	42
295	Evolving multidimensional pharmacological approaches to CNV therapy in AMD. Current Eye Research, 2018, 43, 147-154.	0.7	8
296	Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration. Ophthalmology, 2018, 125, 66-74.	2.5	73
297	Intravitreal Anti-vascular Endothelial Growth Factor Injections to Treat Neovascular Age-related Macular Degeneration: Long-term Treatment Outcomes. Journal of Korean Ophthalmological Society, 2018, 59, 1142.	0.0	3
298	Long-term Treatment Outcome of Intravitreal Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy. Journal of Korean Ophthalmological Society, 2018, 59, 238.	0.0	2
299	Reply. Retina, 2018, 38, e85-e86.	1.0	1
300	Reply. Retina, 2018, 38, e84-e85.	1.0	0
301	Long term outcome after anti-VEGF treatmentâ€"what do we know about the impact of morphological parameters?. Annals of Eye Science, 2018, 3, 57-57.	1.1	0
302	Age related macular degeneration: from evidence based-care to experimental models. Annals of Eye Science, 0, 3, 1-1.	1.1	5
303	Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration. International Journal of Ophthalmology, 2018, 11, 645-649.	0.5	3

#	Article	IF	Citations
304	Quantitative proteomic analysis of aqueous humor from patients with drusen and reticular pseudodrusen in age-related macular degeneration. BMC Ophthalmology, 2018, 18, 289.	0.6	32
305	Myofibroblasts in macular fibrosis secondary to neovascular age-related macular degeneration - the potential sources and molecular cues for their recruitment and activation. EBioMedicine, 2018, 38, 283-291.	2.7	49
306	Prechoroidal Cleft in Type 3 Neovascularization: Incidence, Timing, and Its Association with Visual Outcome. Journal of Ophthalmology, 2018, 2018, 1-8.	0.6	11
307	Effects of Smoking on Outcomes of Antivascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration Smoking and Anti-VEGF Therapy in nAMD. Journal of Ophthalmology, 2018, 2018, 1-7.	0.6	4
308	An update on inflammatory choroidal neovascularization: epidemiology, multimodal imaging, and management. Journal of Ophthalmic Inflammation and Infection, 2018, 8, 13.	1.2	84
309	Age-related macular degeneration. Lancet, The, 2018, 392, 1147-1159.	6.3	958
310	Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-effectiveness Analysis. Journal of Managed Care & Specialty Pharmacy, 2018, , 1-9.	0.5	12
311	Systemic immunosuppression and risk of age-related macular degeneration. PLoS ONE, 2018, 13, e0203492.	1.1	6
312	Human embryonic stem cell-derived retinal pigment epithelium transplants as a potential treatment for wet age-related macular degeneration. Cell Discovery, 2018, 4, 50.	3.1	64
313	The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea. PLoS ONE, 2018, 13, e0206690.	1.1	11
314	Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment. Clinical Ophthalmology, 2018, Volume 12, 1877-1885.	0.9	23
315	Reply. Ophthalmology, 2018, 125, e84-e85.	2.5	0
316	Loss to Follow-up Among Patients With Neovascular Age-Related Macular Degeneration Who Received Intravitreal Antiâ€"Vascular Endothelial Growth Factor Injections. JAMA Ophthalmology, 2018, 136, 1251.	1.4	70
317	Combination of ranibizumab and indomethacin for neovascular age-related macular degeneration: randomized controlled trial. Clinical Ophthalmology, 2018, Volume 12, 587-591.	0.9	4
318	Noninfectious Inflammatory Response following Intravitreal Bevacizumab Injections: Description of a Cluster of Cases in Two Centers and a Review of the Literature. Ophthalmologica, 2018, 240, 163-166.	1.0	8
319	Low incidence of choroidal neovascularization following subthreshold diode micropulse laser (SDM) in high-risk AMD. PLoS ONE, 2018, 13, e0202097.	1.1	21
320	Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells. Korean Journal of Ophthalmology: KJO, 2018, 32, 328.	0.5	0
321	Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance. Clinical Ophthalmology, 2018, Volume 12, 593-600.	0.9	11

#	Article	IF	Citations
322	Safety and Feasibility of a Novel Sparse Optical Coherence Tomography Device for Patient-Delivered Retina Home Monitoring. Translational Vision Science and Technology, 2018, 7, 8.	1.1	44
323	Would intravitreal bevacizumab injection increase risk of cerebral infarction?. European Journal of Neurology, 2018, 25, 1177-1181.	1.7	0
324	In vivo antivascular endothelial growth factor treatment induces corneal endothelium apoptosis in rabbits through changes in p75NTRâ€"proNGF pathway. Journal of Cellular Physiology, 2018, 233, 8874-8883.	2.0	7
325	Quantitative biometry of zebrafish retinal vasculature using optical coherence tomographic angiography. Biomedical Optics Express, 2018, 9, 1244.	1.5	11
326	Multimodal Imaging Patterns for Development of Central Atrophy Secondary to Age-Related Macular Degeneration. , 2018, 59, AMD1.		19
327	Morphological Predictive Features on Spectral-Domain Optical Coherence Tomography for Visual Outcomes in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab. BioMed Research International, 2018, 2018, 1-9.	0.9	3
328	Prediction of Individual Disease Conversion in Early AMD Using Artificial Intelligence. , 2018, 59, 3199.		144
329	Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 608-616.	0.5	18
330	C-Reactive Protein as a Therapeutic Target in Age-Related Macular Degeneration. Frontiers in Immunology, 2018, 9, 808.	2.2	42
331	Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy. Drug Delivery, 2018, 25, 1537-1545.	2.5	12
332	New Therapies of Neovascular AMD beyond Anti-VEGF Injections. Vision (Switzerland), 2018, 2, 15.	0.5	8
333	Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting. Ophthalmology and Therapy, 2018, 7, 361-368.	1.0	37
334	Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab. BMC Ophthalmology, 2018, 18, 20.	0.6	2
335	Endophthalmitis Following Intravitreal Injection. Current Ophthalmology Reports, 2018, 6, 145-151.	0.5	7
336	Past and prognosis of anti-VEGF therapy for wet age-related macular degenerationâ€"the future has begun. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 1553-1555.	1.0	2
337	Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study. Clinical Ophthalmology, 2018, Volume 12, 1137-1147.	0.9	6
338	Bevacizumab Promotes T-Cellâ€"Mediated Collagen Deposition in the Mouse Model of Conjunctival Scarring. , 2018, 59, 1682.		3
339	Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. Journal of Managed Care & Specialty Pharmacy, 2018, 24, S3-S15.	0.5	89

#	Article	IF	Citations
340	Alk1 (Activin Receptor-Like Kinase 1) and Vascular Hyperpermeability in Diabetic Retinopathy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1673-1675.	1.1	1
341	Liquid Biopsy of Vitreous Reveals an Abundant Vesicle Population Consistent With the Size and Morphology of Exosomes. Translational Vision Science and Technology, 2018, 7, 6.	1.1	86
342	New Therapies of Neovascular AMDâ€"Beyond Anti-VEGFs. Vision (Switzerland), 2018, 2, 31.	0.5	9
343	Five-year visual outcomes after anti-VEGF therapy with or without photodynamic therapy for polypoidal choroidal vasculopathy. British Journal of Ophthalmology, 2019, 103, 617-622.	2.1	22
344	Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study. British Journal of Ophthalmology, 2019, 103, 844-848.	2.1	21
345	Comparison of long-term clinical evolution in highly myopic eyes with vertical oval-shaped dome with or without untreated serous retinal detachment. British Journal of Ophthalmology, 2019, 103, 385-389.	2.1	10
346	Accuracy of ultra-wide-field fundus ophthalmoscopy-assisted deep learning, a machine-learning technology, for detecting age-related macular degeneration. International Ophthalmology, 2019, 39, 1269-1275.	0.6	63
347	Optical Coherence Tomography-Based Deep-Learning Models for Classifying Normal and Age-Related Macular Degeneration and Exudative and Non-Exudative Age-Related Macular Degeneration Changes. Ophthalmology and Therapy, 2019, 8, 527-539.	1.0	70
348	Long-Term Management of Neovascular Age-Related Macular Degeneration: ToÂSuspend or Not to Suspend?. Ophthalmology Retina, 2019, 3, 621-622.	1.2	12
349	Optical coherence tomography angiography characteristics of choroidal neovascularization requiring varied dosing frequencies in treat-and-extend management: An analysis of the AVATAR study. PLoS ONE, 2019, 14, e0218889.	1.1	14
350	Outcomes of Suspending VEGF Inhibitors for Neovascular Age-Related Macular Degeneration When Lesions Have Been Inactive for 3 Months. Ophthalmology Retina, 2019, 3, 623-628.	1.2	31
351	Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration . Clinical Ophthalmology, 2019, Volume 13, 1323-1329.	0.9	42
352	Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration . Clinical Ophthalmology, 2019, Volume 13, 1289-1295.	0.9	2
353	A novel dendrimer-based complex co-modified with cyclic RGD hexapeptide and penetratin for noninvasive targeting and penetration of the ocular posterior segment. Drug Delivery, 2019, 26, 989-1001.	2.5	30
355	Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. The Cochrane Library, 2019, 2019, CD005139.	1.5	116
356	Intraocular VEGF deprivation induces degeneration and fibrogenic response in retina. FASEB Journal, 2019, 33, 13920-13934.	0.2	5
357	Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease. Molecular Therapy - Nucleic Acids, 2019, 17, 819-828.	2.3	37
358	Novel method of treating macular degeneration: a patent evaluation (WO2018/107005). Expert Opinion on Therapeutic Patents, 2019, 29, 749-752.	2.4	4

#	Article	IF	Citations
359	Hyaluronic Acidâ€"Antibody Fragment Bioconjugates for Extended Ocular Pharmacokinetics. Bioconjugate Chemistry, 2019, 30, 2782-2789.	1.8	12
360	Five-Year Follow-up of Nonfibrotic Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology, 2019, 126, 743-751.	2.5	20
361	Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology, 2019, 137, 372.	1.4	95
362	EFFECT OF SERIAL ANTERIOR CHAMBER PARACENTESIS ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina, 2019, 39, 1959-1964.	1.0	5
363	Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. Graefe's Archive for Clinical and Experimental Ophthalmology, 2019, 257, 1411-1418.	1.0	15
364	Statins and Age-Related Macular Degeneration: Implications for Dietary Intake. , 2019, , 569-583.		0
365	Recent advances in intraocular sustained-release drug delivery devices. Drug Discovery Today, 2019, 24, 1694-1700.	3.2	49
366	Looking ahead in retinal disease management: highlights of the 2019 angiogenesis, exudation and degeneration symposium. International Journal of Retina and Vitreous, 2019, 5, 22.	0.9	7
367	Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. Expert Opinion on Biological Therapy, 2019, 19, 735-751.	1.4	18
368	Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets. Pharmacological Research, 2019, 146, 104277.	3.1	5
369	Effects of Fucoidans from Five Different Brown Algae on Oxidative Stress and VEGF Interference in Ocular Cells. Marine Drugs, 2019, 17, 258.	2.2	35
370	Longâ€term therapeutic effect in nonhuman primate eye from a single injection of antiâ€VEGF controlled release hydrogel. Bioengineering and Translational Medicine, 2019, 4, e10128.	3.9	20
371	Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema. British Journal of Ophthalmology, 2019, 103, 1356-1360.	2.1	21
372	Current perspectives on established and novel therapies for pathological neovascularization in retinal disease. Biochemical Pharmacology, 2019, 164, 321-325.	2.0	22
373	Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. , 2019, 60, 1088.		26
374	Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a â€œTreat-and-Extendâ€•Regimen. Ophthalmology Retina, 2019, 3, 393-399.	1.2	50
375	Three-Year Follow-Up of Phase 1 and 2a rAAV.sFLT-1 Subretinal Gene Therapy Trials for Exudative Age-Related Macular Degeneration. American Journal of Ophthalmology, 2019, 204, 113-123.	1.7	48
376	Fundus autofluorescence and retinal sensitivity in fellow eyes of age-related macular degeneration in Japan. PLoS ONE, 2019, 14, e0213161.	1.1	3

#	Article	IF	Citations
377	Intravitreal Ets1 siRNA alleviates choroidal neovascularization in a mouse model of age-related macular degeneration. Cell and Tissue Research, 2019, 376, 341-351.	1.5	10
378	Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy. Scientific Reports, 2019, 9, 3620.	1.6	20
379	Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy. Molecular Therapy - Nucleic Acids, 2019, 16, 38-50.	2.3	47
380	Intravitreal conbercept injection for neovascular age-related macular degeneration. International Journal of Ophthalmology, 2019, 12, 252-257.	0.5	9
381	Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part I: A Review of Disease Characterization and Morphological Associations. Ophthalmology and Therapy, 2019, 8, 235-249.	1.0	13
382	Other Therapies in CSCR. , 2019, , 305-316.		0
383	Long-Term Changes in Submacular Choroidal Thickness after Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration: 14-Mo Follow-Up. Current Eye Research, 2019, 44, 908-915.	0.7	9
384	Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye, 2019, 33, 1-21.	1.1	45
385	Targeting P2X7 receptors as a means for treating retinal disease. Drug Discovery Today, 2019, 24, 1598-1605.	3.2	21
386	Mesopic and Dark-Adapted Two-Color Fundus-Controlled Perimetry in Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Translational Vision Science and Technology, 2019, 8, 7.	1.1	25
387	Device design methodology and formulation of a protein therapeutic for sustained release intraocular delivery. Bioengineering and Translational Medicine, 2019, 4, 152-163.	3.9	12
388	The use of real-world evidence for evaluating antiâ€"vascular endothelial growth factor treatment of neovascular age-related macular degeneration. Survey of Ophthalmology, 2019, 64, 707-719.	1.7	25
389	Reply. Ophthalmology, 2019, 126, e19-e20.	2.5	0
390	Is Retinal Metabolic Dysfunction at the Center of the Pathogenesis of Age-related Macular Degeneration?. International Journal of Molecular Sciences, 2019, 20, 762.	1.8	72
391	Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmology, 2019, 4, e000398.	0.8	85
392	Treat-and-extend regimens with anti-vascular endothelial growth factor agents in age-related macular degeneration. Expert Review of Ophthalmology, 2019, 14, 287-307.	0.3	2
393	Microvascular contributions to age-related macular degeneration (AMD): from mechanisms of choriocapillaris aging to novel interventions. GeroScience, 2019, 41, 813-845.	2.1	49
394	Choroidal Neovascularization: Mechanisms of Endothelial Dysfunction. Frontiers in Pharmacology, 2019, 10, 1363.	1.6	57

#	Article	IF	Citations
395	Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8) . Clinical Ophthalmology, 2019, Volume 13, 2461-2467.	0.9	13
396	Upcoming Therapies for Age-related Macular Degeneration. International Ophthalmology Clinics, 2019, 59, 155-171.	0.3	0
397	A case report detailing use of a new intraocular lens with advanced technology, designed specifically for patients with center-involving macular disorders. Medicine (United States), 2019, 98, e16583.	0.4	3
398	Following the Status of Visual Cortex Over Time in Patients With Macular Degeneration Reveals Atrophy of Visually Deprived Brain Regions. , 2019, 60, 5045.		15
399	Factors influencing macular atrophy growth rates in neovascular age-related macular degeneration treated with ranibizumab or aflibercept according to an observe-and-plan regimen. British Journal of Ophthalmology, 2019, 103, 900-905.	2.1	11
400	Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2019, 126, 55-63.	2.5	113
401	Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence. Ophthalmology Retina, 2019, 3, 8-15.e1.	1.2	9
402	Retinal imaging including optical coherence tomography angiography for detecting active choroidal neovascularization in pseudoxanthoma elasticum. Clinical and Experimental Ophthalmology, 2019, 47, 240-249.	1.3	11
403	Transplantation of photoreceptors into the degenerative retina: Current state and future perspectives. Progress in Retinal and Eye Research, 2019, 69, 1-37.	7.3	130
404	The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders. Experimental Eye Research, 2019, 180, 43-52.	1.2	27
405	Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology, 2019, 126, 252-260.	2.5	153
406	Trainee-led versus specialist-led management of neovascular age-related macular degeneration: a registry-based study. British Journal of Ophthalmology, 2019, 103, 1158-1162.	2.1	1
407	Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2019, 126, 64-74.	2.5	22
408	EXIT STRATEGY IN A TREAT-AND-EXTEND REGIMEN FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2019, 39, 27-33.	1.0	27
409	RETINAL PIGMENT EPITHELIUMâ€"CHOROID GRAFT WITH A PERIPHERAL RETINOTOMY FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2019, 39, 288-295.	1.0	12
410	OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina, 2019, 39, 303-313.	1.0	8
411	MACULAR ATROPHY FINDINGS BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY COMPARED WITH FUNDUS AUTOFLUORESCENCE IN TREATED EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina, 2019, 39, 296-302.	1.0	6
412	MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTORâ€"TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2019, 39, 906-917.	1.0	20

#	Article	IF	Citations
413	Macular Atrophy in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 198-210.	2.5	51
414	Innate immune response in retinal homeostasis and inflammatory disorders. Progress in Retinal and Eye Research, 2020, 74, 100778.	7.3	63
415	Ten-Year Treatment Outcomes of Neovascular Age-Related Macular Degeneration from Two Regions. American Journal of Ophthalmology, 2020, 210, 116-124.	1.7	53
416	Updates on Myopia. , 2020, , .		16
417	SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States. Ophthalmology Retina, 2020, 4, 122-133.	1.2	52
418	Realâ€world 10â€year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular ageâ€related macular degeneration. Acta Ophthalmologica, 2020, 98, 132-138.	0.6	30
419	Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration. Ophthalmology, 2020, 127, 186-195.	2.5	306
420	Long-Term Incidence and Growth of Chorioretinal Atrophy in Patients with Polypoidal Choroidal Vasculopathy. Ophthalmologica, 2020, 243, 136-144.	1.0	5
421	Current Concepts in Ophthalmology. , 2020, , .		1
422	Optometry Australia's chairside reference for the diagnosis and management of ageâ€related macular degeneration. Australasian journal of optometry, The, 2020, 103, 254-264.	0.6	12
423	VEGFâ€Trap is a potent modulator of vasoregenerative responses and protects dopaminergic amacrine network integrity in degenerative ischemic neovascular retinopathy. Journal of Neurochemistry, 2020, 153, 390-412.	2.1	10
424	A Review of Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part II. Ophthalmology and Therapy, 2020, 9, 35-75.	1.0	5
425	Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease. JAMA Ophthalmology, 2020, 138, 244.	1.4	54
426	Age-Related Macular Degeneration Preferred Practice PatternÂ®. Ophthalmology, 2020, 127, P1-P65.	2.5	167
427	Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2020, 4, 250-263.	1.2	38
428	Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset. Ophthalmologica, 2020, 243, 1-8.	1.0	66
429	Visual Acuity Outcomes after Antiâ€"Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2020, 4, 3-12.	1.2	15
430	OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2020, 40, 881-890.	1.0	6

#	Article	IF	Citations
431	EVALUATION OF SURGICAL FACTORS AFFECTING VITREOUS HEMORRHAGE FOLLOWING PORT DELIVERY SYSTEM WITH RANIBIZUMAB IMPLANT INSERTION IN A MINIPIG MODEL. Retina, 2020, 40, 1520-1528.	1.0	20
432	TEN-YEAR FOLLOW-UP OF PATIENTS WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL ANTIâ€"VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. Retina, 2020, 40, 1665-1672.	1.0	17
433	Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project. British Journal of Ophthalmology, 2020, 104, 1064-1069.	2.1	10
434	Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration. Journal of International Medical Research, 2020, 48, 030006052093161.	0.4	6
435	Management Strategies and Visual Results for the Treatment of Neovascular Age-Related Macular Degeneration. , 2020, , .		1
436	Agreement of Spectral-Domain OCT with Fluorescein Leakage in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2020, 4, 1054-1058.	1.2	6
437	Differences in uptake and intracellular fate between Bevacizumab and Aflibercept after repetitive long-term treatment in the RPE. Ophthalmic Research, 2020, 64, 369-388.	1.0	3
438	Ten-year survival trends of neovascular age-related macular degeneration at first presentation. British Journal of Ophthalmology, 2021, 105, 1688-1695.	2.1	9
439	Long-Term Follow-up of Patients with Exudative Age-Related Macular Degeneration Treated with Intravitreal Antiâ€"Vascular Endothelial Growth Factor Injections. Ophthalmology Retina, 2020, 4, 1047-1053.	1.2	10
440	Combination of apolipoprotein-A-I/apolipoprotein-A-I binding protein and anti-VEGF treatment overcomes anti-VEGF resistance in choroidal neovascularization in mice. Communications Biology, 2020, 3, 386.	2.0	15
441	HLA-Matched Allogeneic iPS Cells-Derived RPE Transplantation for Macular Degeneration. Journal of Clinical Medicine, 2020, 9, 2217.	1.0	88
442	Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration. BMC Ophthalmology, 2020, 20, 276.	0.6	8
443	Plasma level of lipocalin 2 is increased in neovascular age-related macular degeneration patients, particularly those with macular fibrosis. Immunity and Ageing, 2020, 17, 35.	1.8	8
444	IQGAP1 causes choroidal neovascularization by sustaining VEGFR2-mediated Rac1 activation. Angiogenesis, 2020, 23, 685-698.	3.7	26
445	Blockade of Platelet-Derived Growth Factor Signaling Inhibits Choroidal Neovascularization and Subretinal Fibrosis in Mice. Journal of Clinical Medicine, 2020, 9, 2242.	1.0	9
446	Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/Î"FosBâ€"VCAM-1 axis. Science Advances, 2020, 6, eaaz7815.	4.7	16
447	Management of Fluid in Neovascular Age-related Macular Degeneration: To Mop it, to Dab it, or to Leave it?. Retina, 2020, 40, 1451-1455.	1.0	11
448	Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology, 2020, 138, 835.	1.4	6

#	Article	IF	Citations
449	Slowed Progression of Age-Related Geographic Atrophy Following Subthreshold Laser . Clinical Ophthalmology, 2020, Volume 14, 2983-2993.	0.9	15
450	Trends in Real-World Neovascular AMD Treatment Outcomes in the UK . Clinical Ophthalmology, 2020, Volume 14, 3331-3342.	0.9	29
451	Fibrotic Changes and Endothelial-to-Mesenchymal Transition Promoted by VEGFR2 Antagonism Alter the Therapeutic Effects of VEGFA Pathway Blockage in a Mouse Model of Choroidal Neovascularization. Cells, 2020, 9, 2057.	1.8	14
452	Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up. Journal of Ophthalmology, 2020, 2020, 1-12.	0.6	4
453	Signalling, Metabolic Pathways and Iron Homeostasis in Endothelial Cells in Health, Atherosclerosis and Alzheimerâ€™s Disease. Cells, 2020, 9, 2055.	1.8	20
454	Stem cell therapies for retinal diseases: from bench to bedside. Journal of Molecular Medicine, 2020, 98, 1347-1368.	1.7	12
455	Effect of the Duration of Intraretinal or Subretinal Fluid on the Response to Treatment in Undertreated Age-Related Macular Degeneration. Journal of Ophthalmology, 2020, 2020, 1-8.	0.6	7
456	Fixed Regimen Treatment in Unselected NaÃ¯ve Patients Cohort with Neovascular Age-Related Macular Degeneration. Journal of Ophthalmology, 2020, 2020, 1-8.	0.6	2
457	PREVALENCE AND RISK FACTORS FOR THE DEVELOPMENT OF PHYSICIAN-GRADED SUBRETINAL FIBROSIS IN EYES TREATED FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2020, 40, 2285-2295.	1.0	27
458	Fucoidans as Potential Therapeutics for Age-Related Macular Degenerationâ€"Current Evidence from In Vitro Research. International Journal of Molecular Sciences, 2020, 21, 9272.	1.8	15
459	Recent advances in intraocular and novel drug delivery systems for the treatment of diabetic retinopathy. Expert Opinion on Drug Delivery, 2021, 18, 553-576.	2.4	20
460	Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. International Journal of Molecular Sciences, 2020, 21, 8242.	1.8	82
461	Hyaloid Vasculature as a Major Source of STAT3 ⁺ (Signal Transducer and Activator of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Retinopathy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, e367-e379.	1.1	7
462	Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors. Scientific Reports, 2020, 10, 8036.	1.6	20
463	A Trinity regimen with aflibercept for treatment-naÃ¯ve neovascular age-related macular degeneration: 2-year outcomes. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 1663-1670.	1.0	4
464	Type 1 Choroidal Neovascularization Evolution by Optical Coherence Tomography Angiography: Long-Term Follow-Up. BioMed Research International, 2020, 2020, 1-8.	0.9	3
465	Definition of indicators of appropriateness in the management of neovascular age-related macular degeneration: An expert opinion. European Journal of Ophthalmology, 2020, 30, 795-804.	0.7	2
467	Optical coherence tomography angiography markers associated with treatment response in neovascular age-related macular degeneration. European Journal of Ophthalmology, 2020, 31, 112067212092579.	0.7	5

#	Article	IF	Citations
468	Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen. Ophthalmology, 2020, 127, 1663-1673.	2.5	23
469	Periostin and tenascin-C interaction promotes angiogenesis in ischemic proliferative retinopathy. Scientific Reports, 2020, 10, 9299.	1.6	15
470	Register your interest. Clinical and Experimental Ophthalmology, 2020, 48, 421-423.	1.3	1
471	Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2020, 218, 225-241.	1.7	22
472	Inhibiting NF-ÎºB Signaling Activation Reduces Retinal Neovascularization by Promoting a Polarization Shift in Macrophages. , 2020, 61, 4.		21
473	Three-Year Outcomes of Patients with Neovascular Age-Related Macular Degeneration Treated with Aflibercept under the National Health Insurance Program in Taiwan. Journal of Ophthalmology, 2020, 2020, 1-8.	0.6	5
474	Integrated bioinformatics analysis of aberrantly-methylated differentially-expressed genes and pathways in age-related macular degeneration. BMC Ophthalmology, 2020, 20, 119.	0.6	5
475	Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents. Canadian Journal of Ophthalmology, 2020, 55, 286-292.	0.4	14
476	Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration. PLoS ONE, 2020, 15, e0229342.	1.1	4
477	Tenâ€year outcomes of antiâ€vascular endothelial growth factor treatment for neovascular ageâ€related macular disease: A singleâ€centre French study. Clinical and Experimental Ophthalmology, 2020, 48, 636-643.	1.3	23
478	Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study . Clinical Ophthalmology, 2020, Volume 14, 1473-1481.	0.9	4
479	Long-Term Visual/Anatomic Outcome in Patients with Fovea-Involving Fibrovascular Pigment Epithelium Detachment Presenting Choroidal Neovascularization on Optical Coherence Tomography Angiography. Journal of Clinical Medicine, 2020, 9, 1863.	1.0	5
480	Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Results from real-life setting. European Journal of Ophthalmology, 2021, 31, 1940-1944.	0.7	9
481	Eliminating Visual Acuity and Dilated Fundus Examinations Improves Cost Efficiency of Performing Optical Coherence Tomogrpahyâ€"Guided Intravitreal Injections. American Journal of Ophthalmology, 2020, 219, 222-230.	1.7	14
482	Mitochondrial dysfunction in age-related macular degeneration: melatonin as a potential treatment. Expert Opinion on Therapeutic Targets, 2020, 24, 359-378.	1.5	46
483	Brolucizumab: an evolution in treatment for neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2020, 15, 71-81.	0.3	0
484	Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration. Journal of Ophthalmology, 2020, 2020, 1-7.	0.6	3
485	Different conbercept injection strategies for the treatment of exudative age-related macular degeneration. Medicine (United States), 2020, 99, e19007.	0.4	5

#	Article	IF	Citations
486	Essential contribution of macrophage Tie2 signal mediated autophagy in laser-induced choroidal neovascularization. Experimental Eye Research, 2020, 193, 107972.	1.2	8
487	OCT Angiography Features of Neovascularization as Predictive Factors for Frequent Recurrence in Age-Related Macular Degeneration. American Journal of Ophthalmology, 2020, 213, 109-119.	1.7	23
488	Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration. Eye, 2020, 34, 1888-1896.	1.1	51
489	Oral Delivery of a Tetrameric Tripeptide Inhibitor of VEGFR1 Suppresses Pathological Choroid Neovascularization. International Journal of Molecular Sciences, 2020, 21, 410.	1.8	8
490	A G-Protein Coupled Receptor and Macular Degeneration. Cells, 2020, 9, 910.	1.8	9
491	Outcome of treatment for neovascular age-related macular degeneration by practice-based ophthalmologists compared with a macula clinic. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 1405-1410.	1.0	1
492	Leveraging Nuclear Receptors as Targets for Pathological Ocular Vascular Diseases. International Journal of Molecular Sciences, 2020, 21, 2889.	1.8	9
493	Four-Year Outcome of Aflibercept Treatment-NaÃ¯ve Patients for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting. Journal of Ophthalmology, 2020, 2020, 1-7.	0.6	7
494	Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 1411-1417.	1.0	8
495	Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial. Ophthalmology, 2020, 127, 1191-1200.	2.5	20
496	Real-Life Data in the Treatment of Neovascular Age-Related Macular Degeneration: Results from the Imaculaweb Registry Evaluated in a Single Italian Medical Retina Center. Ophthalmologica, 2020, 243, 453-460.	1.0	14
497	Intraocular Pharmacokinetics of 10-fold Intravitreal Ranibizumab Injection Dose in Rabbits. Translational Vision Science and Technology, 2020, 9, 7.	1.1	19
498	Risk factors for subretinal fibrosis after anti-VEGF treatment of myopic choroidal neovascularisation. British Journal of Ophthalmology, 2021, 105, 103-108.	2.1	10
499	Macular atrophy development in neovascular age-related macular degeneration during first year of treatment: Incidence and risk factors. European Journal of Ophthalmology, 2021, 31, 521-528.	0.7	2
500	Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration. Japanese Journal of Ophthalmology, 2021, 65, 69-76.	0.9	8
501	Simple Vision Function Tests that Distinguish Eyes with Early to Intermediate Age-related Macular Degeneration. Ophthalmic Epidemiology, 2021, 28, 93-104.	0.8	5
502	Statement of the German Ophthalmological Society (DOG), the German Retina Society (GRS), and the Professional Association of German Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related macular degeneration. Ophthalmologe, 2021, 118, 31-39.	0.4	8
503	Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2021, 128, 234-247.	2.5	95

#	Article	IF	Citations
504	A Cost-Benefit Analysis of VEGF-Inhibitor Therapy for Neovascular Age-Related Macular Degeneration in the United States. American Journal of Ophthalmology, 2021, 223, 405-429.	1.7	12
505	Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Progress in Retinal and Eye Research, 2021, 82, 100906.	7.3	133
506	Long-term Antiâ€"Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study. Ophthalmology Retina, 2021, 5, 511-518.	1.2	10
507	Revisiting the role of factor H in age-related macular degeneration: Insights from complement-mediated renal disease and rare genetic variants. Survey of Ophthalmology, 2021, 66, 378-401.	1.7	19
508	Localized Optical Coherence Tomography Precursors of Macular Atrophy and Fibrotic Scar in the Comparison of Age-Related Macular Degeneration Treatments Trials. American Journal of Ophthalmology, 2021, 223, 338-347.	1.7	9
509	Nonclinical Toxicology and Biocompatibility Program Supporting Clinical Development and Registration of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration. Toxicologic Pathology, 2021, 49, 663-672.	0.9	8
510	Deep Learningâ€"Based Detection of Endothelial Tip Cells in the Oxygen-Induced Retinopathy Model. Toxicologic Pathology, 2021, 49, 862-871.	0.9	1
511	Dual-acting therapeutic proteins for intraocular use. Drug Discovery Today, 2021, 26, 44-55.	3.2	1
513	Pharmacotherapy of Age-Related Macular Degeneration. , 2021, , 1-26.		0
514	Age-Related Macular Degeneration Revisited: From Pathology and Cellular Stress to Potential Therapies. Frontiers in Cell and Developmental Biology, 2020, 8, 612812.	1.8	50
515	Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study. BMC Ophthalmology, 2021, 21, 58.	0.6	4
516	Efficacy of Psychiatric Treatment to Treat a Specific Phobia of Intravitreal Injections in a Patient with Neovascular Age-Related Macular Degeneration. Case Reports in Ophthalmology, 2021, 12, 48-56.	0.3	1
517	Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology, 2021, Volume 15, 279-287.	0.9	12
518	Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 2085-2093.	1.0	13
519	Long-Term Safety Evaluation of Continuous Intraocular Delivery of Aflibercept by the Intravitreal Gene Therapy Candidate ADVM-022 in Nonhuman Primates. Translational Vision Science and Technology, 2021, 10, 34.	1.1	14
521	Ten-year outcome of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. Indian Journal of Ophthalmology, 2021, 69, 2350.	0.5	4
522	Reactivation of CNV after discontinuation of bevacizumab treatment of age-related macular degeneration. Ophthalmologica, 2021, 244, 200-207.	1.0	1
523	Identifying early symptoms of choroidal neovascularisation in second eyes of patients with unilateral wet age related macular degeneration using a telephone evaluation method. Eye, 2021, 35, 3028-3034.	1.1	0

#	Article	IF	Citations
524	Reading Speed after Anti-vascular Endothelial Growth Factor Therapy in Patients with Wet Age-related Macular Degeneration. Journal of Korean Ophthalmological Society, 2021, 62, 68-76.	0.0	0
525	Novel treatments and genetics of age-related macular degeneration-a narrative review. Annals of Eye Science, 0, 6, 38-38.	1.1	1
526	Emerging Therapies in Nonexudative Age-Related Macular Degeneration in 2020. Asia-Pacific Journal of Ophthalmology, 2021, 10, 408-416.	1.3	14
527	Longer-acting treatments for neovascular age-related macular degenerationâ€"present and future. Eye, 2021, 35, 1111-1116.	1.1	17
528	Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD)Ââ€"Âa meta-analysis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 2181-2192.	1.0	14
529	Aflibercept for treatment-naÃ¯ve diabetic macula oedema in a multi-ethnic population: Real-world outcomes from North West London. PLoS ONE, 2021, 16, e0246626.	1.1	5
530	Intraocular Injection of HyStem Hydrogel Is Tolerated Well in the Rabbit Eye. Journal of Ocular Pharmacology and Therapeutics, 2021, 37, 60-71.	0.6	4
531	Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration. Journal of Clinical Medicine, 2021, 10, 1355.	1.0	17
532	Treatment of Experimental Choroidal Neovascularization via RUNX1 Inhibition. American Journal of Pathology, 2021, 191, 418-424.	1.9	9
533	Repurposing bortezomib for choroidal neovascularization treatment via antagonizing VEGF-A and PDGF-D mediated signaling. Experimental Eye Research, 2021, 204, 108446.	1.2	6
534	Visual acuity and progression of macular atrophy in patients receiving intravitreal anti-VEGF for age-related macular degeneration. European Journal of Ophthalmology, 2021, , 112067212110017.	0.7	1
535	Reliability of Retinal Pathology Quantification in Age-Related Macular Degeneration: Implications for Clinical Trials and Machine Learning Applications. Translational Vision Science and Technology, 2021, 10, 4.	1.1	16
536	Loss of function of the carbon catabolite repressor CreA leads to low but inducerâ€independent expression from the feruloyl esterase B promoter in Aspergillus niger. Biotechnology Letters, 2021, 43, 1323-1336.	1.1	4
537	Three-year clinical and optical coherence tomography follow-up after stereotactic radiotherapy for neovascular age-related macular degeneration. Advances in Medical Sciences, 2021, 66, 215-220.	0.9	1
538	Aflibercept in real-life for the treatment of age-related macular degeneration using a treat and extend protocol: The Armada study. European Journal of Ophthalmology, 2022, 32, 356-363.	0.7	1
539	Current status of home monitoring technology for age-related macular degeneration. Current Opinion in Ophthalmology, 2021, 32, 240-246.	1.3	10
540	Morphological features and prognostic significance of multilayered pigment epithelium detachment in age-related macular degeneration. British Journal of Ophthalmology, 2021, , bjophthalmol-2020-318616.	2.1	0
541	Long-Term Visual Outcome in Inferior Posterior Staphyloma and Efficacy of Treatment for Complicated Choroidal Neovascularization. American Journal of Ophthalmology, 2021, 229, 152-159.	1.7	2

#	Article	IF	Citations
542	Anti-VEGF Drugs Influence Epigenetic Regulation and AMD-Specific Molecular Markers in ARPE-19 Cells. Cells, 2021, 10, 878.	1.8	9
543	Visual Outcomes after Anti-VEGF Therapy for Exudative Age-Related Macular Degeneration in a Real-Life Setting. Klinische Monatsblatter Fur Augenheilkunde, 2021, 238, 396-402.	0.3	2
544	New Drugs in the Pipeline for the Management of AMD. , 0, , .		0
546	New insights into oxidative stress and immune mechanisms involved in age-related macular degeneration tackled by novel therapies. Neuropharmacology, 2021, 188, 108513.	2.0	12
547	One year outcomes of treat and extend and pro re nata (PRN) treatment regimens with aflibercept for polypoidal choroidal vasculopathy. European Journal of Ophthalmology, 2021, 31, 2868-2875.	0.7	4
548	Continued anti-VEGF treatment does not prevent recurrences in eyes with stable neovascular age-related macular degeneration using a treat-and-extend regimen: a retrospective case series. Eye, 2022, 36, 862-868.	1.1	10
549	PIGMENT EPITHELIAL DETACHMENT IN AGE-RELATED MACULAR DEGENERATION. Retina, 2021, 41, 2229-2235.	1.0	2
550	Emerging therapies and their delivery for treating ageâ€related macular degeneration. British Journal of Pharmacology, 2022, 179, 1908-1937.	2.7	23
551	Age-related macular degeneration. Nature Reviews Disease Primers, 2021, 7, 31.	18.1	340
552	Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles. British Journal of Ophthalmology, 2022, 106, 1555-1560.	2.1	6
553	Evaluation of Long-Lasting Potential of Suprachoroidal Axitinib Suspension Via Ocular and Systemic Disposition in Rabbits. Translational Vision Science and Technology, 2021, 10, 19.	1.1	7
554	A small molecular multi-targeting tyrosine kinase inhibitor, anlotinib, inhibits pathological ocular neovascularization. Biomedicine and Pharmacotherapy, 2021, 138, 111493.	2.5	11
555	Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer. Cells, 2021, 10, 1617.	1.8	11
556	Treat and extend paradigm in management of neovascular age-related macular degeneration: current practice and future directions. Expert Review of Ophthalmology, 2021, 16, 267-286.	0.3	0
557	Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration. Translational Vision Science and Technology, 2021, 10, 30.	1.1	14
558	Active Rap1â€mediated inhibition of choroidal neovascularization requires interactions with IQGAP1 in choroidal endothelial cells. FASEB Journal, 2021, 35, e21642.	0.2	3
559	LONG-TERM COURSE AND VISUAL OUTCOMES OF PRECHOROIDAL CLEFT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY. Retina, 2021, 41, 2436-2445.	1.0	2
560	Effect of Long-term Anti-VEGF Treatment on Viability and Function of RPE Cells. Current Eye Research, 2021, , 1-8.	0.7	3

#	Article	IF	Citations
561	A comparative study between ranibizumab and its first biosimilar razumab in terms of efficacy and safety in DME, RVO and wet AMD associated with CNVM. Indian Journal of Clinical and Experimental Ophthalmology, 2021, 7, 346-351.	0.1	0
562	Neovascular ageâ€related macular degeneration: A review of findings from the realâ€world Fight Retinal Blindness! registry. Clinical and Experimental Ophthalmology, 2021, 49, 652-663.	1.3	15
563	Microfluidic systems to examine MÃ¼ller glia responses to anti-VEGF treatments. Eye, 2021, 35, 3189-3191.	1.1	1
564	THE IMPACT OF DISEASE ACTIVITY ON 5-YEAR OUTCOMES IN PATIENTS UNDERGOING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2022, 42, 95-106.	1.0	6
565	CM082, a novel VEGF receptor tyrosine kinase inhibitor, can inhibit angiogenesis in vitro and in vivo. Microvascular Research, 2021, 136, 104146.	1.1	3
566	Kinins and Their Receptors as Potential Therapeutic Targets in Retinal Pathologies. Cells, 2021, 10, 1913.	1.8	12
568	Predictive Factors for Long-Term Outcomes of Cataract Surgery in Patients Receiving Active Treatment for Neovascular Age-Related Macular Degeneration. Journal of Clinical Medicine, 2021, 10, 3124.	1.0	3
569	Clinical efficacy of intravitreal corticoid as an adjunctive therapy to anti-VEGF treatment of neovascular age-related macular degeneration: a Meta-analysis. International Journal of Ophthalmology, 2021, 14, 1092-1099.	0.5	1
570	Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option. Journal of Immunology Research, 2021, 2021, 1-15.	0.9	20
571	Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol without recurrence. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 3665-3673.	1.0	5
572	The Challenges of Treating Neovascular Age-Related Macular Degeneration. Klinische Monatsblatter Fur Augenheilkunde, 2021, , .	0.3	3
573	Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Scientific Reports, 2021, 11, 14623.	1.6	6
574	Evolving Treatment Patterns and Outcomes of Neovascular Age-Related Macular Degeneration Over a Decade. Ophthalmology Retina, 2021, 5, e11-e22.	1.2	9
575	OUTCOMES IN PATIENTS RESUMING INTRAVITREAL ANTIâ€"VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOLLOWING TREATMENT DELAY DURING THE CORONAVIRUS-19 PANDEMIC. Retina, 2021, 41, 2456-2461.	1.0	11
576	Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration â€" Current Perspectives. Clinical Ophthalmology, 2021, Volume 15, 3351-3367.	0.9	15
577	Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study. BMC Ophthalmology, 2021, 21, 300.	0.6	13
578	Central retinal thickness fluctuations in patients treated with anti-VEGF for neovascular age related macular degeneration. European Journal of Ophthalmology, 2021, , 112067212110378.	0.7	5
579	Long-term outcomes of polypoidal choroidal vasculopathy in comparison with typical exudative age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 83-92.	1.0	3

#	Article	IF	Citations
580	The ILâ€23/ILâ€17 axis promotes the formation of retinal neovascularization by activating the NLRP3 inflammasome in macrophages in an experimental retinopathy mouse model. Immunology, 2021, 164, 803-816.	2.0	4
581	Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials. Japanese Journal of Ophthalmology, 2021, 65, 741-760.	0.9	7
582	Immunological aspects of RPE cell transplantation. Progress in Retinal and Eye Research, 2021, 84, 100950.	7.3	39
583	Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy. Ophthalmology, 2021, 128, 1325-1336.	2.5	52
584	Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy. British Journal of Ophthalmology, 2023, 107, 399-405.	2.1	11
585	Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1260-1272.	0.5	6
586	Vitreous Noise on Optical Coherence Tomography as an Early Finding of Brolucizumab-Related Intraocular Inflammation. Case Reports in Ophthalmology, 2022, 12, 797-803.	0.3	2
587	Long-Term Outcomes of Bacillary Layer Detachment in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2022, 6, 185-195.	1.2	13
588	To the Question of Terminology, Expert Criteria for Evaluating the Effectiveness of Antiangiogenic Therapy and the Prevalence of Refractory Forms of Neovascular Age-Related Macular Degeneration. Review. Oftalmologiya, 2021, 18, 389-398.	0.2	1
589	Current Understanding of Polypoidal Choroidal Vasculopathy. Essentials in Ophthalmology, 2021, , 61-71.	0.0	0
590	PDGF Receptor Alpha Signaling Is Key for MÃ¼ller Cell Homeostasis Functions. International Journal of Molecular Sciences, 2021, 22, 1174.	1.8	4
591	Principal Cause of Poor Visual Acuity after Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2021, 5, 23-31.	1.2	8
592	Clinical efficacy and safety of RazumabÂ® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab. Indian Journal of Ophthalmology, 2021, 69, 347.	0.5	15
593	Extracellular vesicles mediate cellular interactions in renal diseasesâ€"Novel views of intercellular communications in the kidney. Journal of Cellular Physiology, 2021, 236, 5482-5494.	2.0	6
594	Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives. Pharmaceutics, 2021, 13, 108.	2.0	82
595	Four-year outcomes of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a treat-and-extend regimen in Japanese patients. Therapeutic Advances in Ophthalmology, 2021, 13, 251584142098458.	0.8	3
596	Current Management of Age-Related Macular Degeneration. Advances in Experimental Medicine and Biology, 2021, 1256, 295-314.	0.8	6
597	Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology, 2021, Volume 15, 189-194.	0.9	1

#	Article	IF	Citations
598	RPE and the Vascular Endothelial Growth Factor. , 2020, , 85-99.		1
599	Angiogenesis-Based Therapies for Eye Diseases. , 2017, , 259-297.		2
600	Restoring Physiologic Barriers Against Neovascular Invasion. Essentials in Ophthalmology, 2015, , 87-95.	0.0	1
601	Preclinical challenges for developing long acting intravitreal medicines. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 153, 130-149.	2.0	21
602	Systemic counterregulatory response of angiopoietinâ€2 after aflibercept therapy for nAMD: a potential escape mechanism. Acta Ophthalmologica, 2021, 99, e869-e875.	0.6	3
603	A novel device for rapid, safe and precise delivery of intravitreal injections. BMJ Innovations, 2019, 5, 8-12.	1.0	1
604	Anti-VEGF therapy: higher potency and long-lasting antagonism are not necessarily better. Journal of Clinical Investigation, 2019, 129, 3032-3034.	3.9	40
605	Recent developments in the treatment of age-related macular degeneration. Journal of Clinical Investigation, 2014, 124, 1430-1438.	3.9	171
606	VEGF regulates local inhibitory complement proteins in the eye and kidney. Journal of Clinical Investigation, 2016, 127, 199-214.	3.9	121
607	ATN-161 as an Integrin Î±5Î²1 Antagonist Depresses Ocular Neovascularization by Promoting New Vascular Endothelial Cell Apoptosis. Medical Science Monitor, 2018, 24, 5860-5873.	0.5	11
608	Diabetes Mellitus and Risk of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e108196.	1.1	70
609	Fundus autofluorescence of retinal angiomatous proliferation. PLoS ONE, 2020, 15, e0243458.	1.1	2
610	Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study. PLoS ONE, 2020, 15, e0244183.	1.1	7
612	Six-year outcomes in neovascular age-related macular degeneration with ranibizumab. International Journal of Ophthalmology, 2017, 10, 81-90.	0.5	18
613	Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes. Journal of Ophthalmic and Vision Research, 2020, 15, 341-350.	0.7	5
614	Calcitriol and non-calcemic vitamin D analogue, 22-oxacalcitriol, attenuate developmental and pathological choroidal vasculature angiogenesis ex vivo and in vivo. Oncotarget, 2020, 11, 493-509.	0.8	8
615	Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models. Oncotarget, 2015, 6, 10563-10576.	0.8	24
616	Cholesterol homeostasis, macrophage malfunction and age-related macular degeneration. Annals of Translational Medicine, 2018, 6, S55-S55.	0.7	6

#	Article	IF	Citations
617	Treat and Extend Dosing Regimen with Anti-vascular Endothelial Growth Factor Agents for Neovascular Age-related Macular Degeneration. American Journal of Ophthalmic Clinical Trials, 0, 1, 1.	0.0	10
618	Accuracy of fundus autofluorescence imaging for the diagnosis and monitoring of retinal conditions: a systematic review. Health Technology Assessment, 2016, 20, 1-108.	1.3	5
619	Effects of the COVID-19 Pandemic on Anti-vascular Endothelial Growth Factor Treatment in China. Frontiers in Medicine, 2020, 7, 576275.	1.2	31
620	Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2015, 46, 542-549.	0.4	5
621	Predictors of Macular Atrophy Detected by Fundus Autofluorescence in Patients With Neovascular Age-Related Macular Degeneration After Long-Term Ranibizumab Treatment. Ophthalmic Surgery Lasers and Imaging Retina, 2016, 47, 224-231.	0.4	16
622	Influence of Retinal Pathology on the Reliability of Macular Thickness Measurement: A Comparison Between Optical Coherence Tomography Devices. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 319-325.	0.4	10
623	36-Month Evaluation of Intravitreous Aflibercept Injection for Wet Age-Related Macular Degeneration in Patients Previously Treated With Ranibizumab or Bevacizumab. Ophthalmic Surgery Lasers and Imaging Retina, 2018, 49, 179-185.	0.4	2
624	Effects of Brimonidine on Retinal Pigment Epithelial Cells and MÃ¼ller Cells Exposed to Amyloid-Beta 1â€“42 Peptide In Vitro. Ophthalmic Surgery Lasers and Imaging Retina, 2018, 49, S23-S28.	0.4	6
625	Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System. Ophthalmic Surgery Lasers and Imaging Retina, 2018, 49, 913-917.	0.4	11
626	Classification of Strokes in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor. Ophthalmic Surgery Lasers and Imaging Retina, 2019, 50, e140-e157.	0.4	12
627	Intravitreal injections: A review of pharmacological agents and techniques. Journal of Clinical Ophthalmology and Research, 2016, 4, 51.	0.1	12
628	Tissue plasminogen activator-assisted vitrectomy for submacular hemorrhage due to age-related macular degeneration. Indian Journal of Ophthalmology, 2017, 65, 482.	0.5	8
629	Intravitreal injection of anti-vascular endothelial growth factor agents for ocular vascular diseases: Clinical practice guideline. Journal of Ophthalmic and Vision Research, 2018, 13, 158.	0.7	23
630	Evaluation of Aflibercept Treatment Responses in Eyes with Bevacizumab/Ranibizumab-resistant Wet Age-related Macular Degeneration. TÃ¼rk Oftalmoloji Dergisi, 2017, 47, 133-137.	0.4	8
631	Risk-based Algorithm-guided Treatment Protocol for the Management of Neovascular Age-related Macular Degeneration. TÃ¼rk Oftalmoloji Dergisi, 2019, 49, 258-269.	0.4	3
632	Age-related macular degeneration treatment in the era of molecular medicine. World Journal of Ophthalmology, 2014, 4, 130.	0.1	1
633	Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin. ELife, 2020, 9, .	2.8	65
634	Efficacy of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-Related Macular Degeneration and Systemic Cardiovascular Risk Factors. Journal of Clinical Medicine, 2021, 10, 4595.	1.0	4

#	Article	IF	Citations
635	Development of Macular Atrophy in Patients with Wet Age-Related Macular Degeneration Receiving Anti-VEGF Treatment. Ophthalmologica, 2022, 245, 204-217.	1.0	16
636	Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab. Clinical Ophthalmology, 2021, Volume 15, 4073-4079.	0.9	6
637	Updates in deep learning research in ophthalmology. Clinical Science, 2021, 135, 2357-2376.	1.8	19
638	Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update. BioDrugs, 2021, 35, 673-692.	2.2	19
639	Pro-inflammatory activation changes intracellular transport of bevacizumab in the retinal pigment epithelium in vitro. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 857-872.	1.0	2
641	Anti-Angiogenic Gene Therapy: Basic Science and Challenges for Translation into the Clinic. Essentials in Ophthalmology, 2016, , 173-188.	0.0	0
642	Thinking Beyond Wet Age-Related Macular Degeneration. Delhi Journal of Ophthalmology, 2016, 26, 210-217.	0.0	0
643	Context for Protons as Adjunctive Therapy in Neovascular Age-Related Macular Degeneration: A Review. International Journal of Particle Therapy, 2016, 2, 555-569.	0.9	0
644	Paradigm of Susceptibility Genes in AMD and PCV. Essentials in Ophthalmology, 2017, , 169-192.	0.0	1
645	Unique Genetic Signatures in Asian Age-Related Macular Degeneration: An Opportunity for Drug Development. Essentials in Ophthalmology, 2017, , 497-507.	0.0	0
646	Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab. International Journal of Ophthalmology, 2017, 10, 423-426.	0.5	3
647	Induction of vascular endothelial growth factor receptor expression in human umbilical vein endothelial cells after repeated bevacizumab treatment in vitro. International Journal of Ophthalmology, 2017, 10, 1064-1068.	0.5	1
648	Our experience in visual functions' improvement in patiens with â€œwetâ€•age-related macular degeneration at switching from one anti-VEGF agent to another. Ophthalmology Journal, 2017, 10, 67-73.	0.1	1
650	Treated exudative CNV: short-term and long-term real-life evolution. Minerva Oftalmologica, 2018, 60, .	0.1	0
651	Long-Term Visual Outcomes in Patients with Neovascular AMD Who Exhibited Visual Acuity of 0.1 or Worse at 5th Injection. Journal of Retina, 2018, 3, 64-70.	0.1	0
652	Comment on â€œAssessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degenerationâ€• International Journal of Ophthalmology, 2018, 11, 1884-1886.	0.5	2
654	Clinical Course of Patients with Neovascular Age-related Macular Degeneration Who Experienced Visual Deterioration after Treatment despite Initially Good Visual Acuity. Journal of Retina, 2019, 4, 10-16.	0.1	0
655	Clinical Management of Myopia in Adults: Treatment of Myopic CNV. , 2020, , 271-288.		0

#	Article	IF	Citations
656	Recent Developments in Maculopathy. , 2020, , 141-163.		0
658	Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology, 2021, Volume 15, 4317-4326.	0.9	15
659	Mitophagy Protects the Retina Against Anti-Vascular Endothelial Growth Factor Therapy-Driven Hypoxia via Hypoxia-Inducible Factor-1Î± Signaling. Frontiers in Cell and Developmental Biology, 2021, 9, 727822.	1.8	10
660	TANDEM TRIAL: a factorial randomised controlled trial of dose and review schedule of bevacizumab (Avastin) for neovascular macular degeneration in the East Midlands. BMJ Open Ophthalmology, 2020, 5, e000588.	0.8	0
662	Side Effects of Brolucizumab. Journal of Ophthalmic and Vision Research, 2021, 16, 670-675.	0.7	6
663	Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis. Translational Vision Science and Technology, 2021, 10, 5.	1.1	4
664	CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2022, 42, 503-510.	1.0	5
665	Association of Smoking, Alcohol Consumption, Blood Pressure, Body Mass Index, and Glycemic Risk Factors With Age-Related Macular Degeneration. JAMA Ophthalmology, 2021, 139, 1299.	1.4	29
667	Long-term Outcomes of Treat and Extend Regimen of Anti-vascular Endothelial Growth Factor in Neovascular Age-related Macular Degeneration. Journal of Ophthalmic and Vision Research, 2020, 15, 331-340.	0.7	5
669	Endothelial NADPH oxidase 4 mediates vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of retinopathy of prematurity. Molecular Vision, 2014, 20, 231-41.	1.1	58
670	Retinal pigment epithelial tears in the era of intravitreal pharmacotherapy: risk factors, pathogenesis, prognosis and treatment (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society, 2014, 112, 142-59.	1.4	33
671	Modern Strategies to Save Sight in Diabetes. Missouri Medicine, 2016, 113, 372-377.	0.3	0
672	Use of Fundus Autofluorescence Combined with Optical Coherence Tomography for Diagnose of Geographic Atrophy in Age-Related Macular Degeneration. Medical Hypothesis, Discovery, and Innovation in Ophthalmology, 2019, 8, 298-305.	0.4	2
673	Voluntary Exercise Suppresses Choroidal Neovascularization in Mice. , 2020, 61, 52.		1
674	Clinical Outcomes of Aflibercept Treatment for Treatment-naive Exudative Age-related Macular Degeneration. Journal of Retina, 2021, 6, 99-109.	0.1	0
675	Exploring Consensus on Preventive Measures and Identification of Patients at Risk of Age-Related Macular Degeneration Using the Delphi Process. Journal of Clinical Medicine, 2021, 10, 5432.	1.0	2
676	The Influence of COVID-19 on the Stability of Patients with Neovascular Age-Related Macular Degeneration with Different Treatment Regimens. Advances in Therapy, 2022, 39, 1568-1581.	1.3	4
677	Retinal Diseases Regulated by Hypoxiaâ€"Basic and Clinical Perspectives: A Comprehensive Review. Journal of Clinical Medicine, 2021, 10, 5496.	1.0	11

#	Article	IF	Citations
678	Role of inflammasome activation in neovascular ageâ€related macular degeneration. FEBS Journal, 2023, 290, 28-36.	2.2	14
679	Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis. Canadian Journal of Ophthalmology, 2023, 58, 252-261.	0.4	15
680	Morphologic and Microvascular Differences Between Macular Neovascularization With and Without Subretinal Fibrosis. Translational Vision Science and Technology, 2021, 10, 1.	1.1	11
681	Recommendations of the treat-and-extend regimen for neovascular age-related macular degeneration: 2020 updates. Hong Kong Journal of Ophthalmology: the Official Publication of the College of Ophthalmologists of Hong Kong = Xianggang Yan Ke Xue Kan: Xianggang Yan Ke Yi Xue Yuan, 2022, 25, 39-46.	0.3	1
682	Can the Onset of Neovascular Age-Related Macular Degeneration Be an Acceptable Endpoint for Prophylactic Clinical Trials?. Ophthalmologica, 2021, 244, 379-386.	1.0	1
683	Implantable Drug Delivery Systems and Foreign Body Reaction: Traversing the Current Clinical Landscape. Bioengineering, 2021, 8, 205.	1.6	23
684	Discovery and Development of the Quininib Series of Ocular Drugs. Journal of Ocular Pharmacology and Therapeutics, 2022, 38, 33-42.	0.6	0
685	Baseline predictors for subretinal fibrosis in neovascular age-related macular degeneration. Scientific Reports, 2022, 12, 88.	1.6	12
686	Vitreous microparticles contain apoptotic signals suggesting a diabetic vitreopathy. International Journal of Ophthalmology, 2022, 15, 89-97.	0.5	0
687	Treatment of macular diseases: an overview of key randomized clinical trials. Rossiiskii Oftal'mologicheskii Zhurnal, 2022, 14, 137-148.	0.1	2
688	The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review. Experimental Eye Research, 2022, 217, 108910.	1.2	12
689	Real-world effectiveness of screening programs for age-related macular degeneration: amended Japanese specific health checkups and augmented screening programs with OCT or AI. Japanese Journal of Ophthalmology, 2022, 66, 19-32.	0.9	6
690	Update of application of olfactory ensheathing cells and stem cells/exosomes in the treatment of retinal disorders. Stem Cell Research and Therapy, 2022, 13, 11.	2.4	4
691	Gene-Based Therapeutics for Inherited Retinal Diseases. Frontiers in Genetics, 2021, 12, 794805.	1.1	24
692	Transcriptomic analysis of choroidal neovascularization reveals dysregulation of immune and fibrosis pathways that are attenuated by a novel anti-fibrotic treatment. Scientific Reports, 2022, 12, 859.	1.6	5
693	Disease progression pathways of wet AMD: opportunities for new target discovery. Expert Opinion on Therapeutic Targets, 2022, 26, 5-12.	1.5	8
694	Automated evaluation of retinal pigment epithelium disease area in eyes with age-related macular degeneration. Scientific Reports, 2022, 12, 892.	1.6	2
695	Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept. International Journal of Retina and Vitreous, 2022, 8, 11.	0.9	2

#	Article	IF	Citations
696	Treatment Outcome of Wet Age-Related Macular Degeneration Management in Thailand: A Retrospective Real-World Study (TOWER Study). Ophthalmology and Therapy, 2022, 11, 739-757.	1.0	7
697	A validated analysis pipeline for mass spectrometry-based vitreous proteomics: new insights into proliferative diabetic retinopathy. Clinical Proteomics, 2021, 18, 28.	1.1	4
698	Risk factors for emerging intraocular inflammation after intravitreal brolucizumab injection for age-related macular degeneration. PLoS ONE, 2021, 16, e0259879.	1.1	25
699	Intraocular Cytokine Changes in Patients with Polypoidal Choroidal Vasculopathy Treated with Ranibizumab. Journal of Korean Ophthalmological Society, 2022, 63, 166-174.	0.0	0
700	Safety and therapeutic effects of orally administered AKST4290 in newly diagnosed neovascular age-related macular degeneration. Retina, 2022, Publish Ahead of Print, 1038-1046.	1.0	6
701	Progression of age-related macular degeneration in eyes with abnormal fundus autofluorescence in a Japanese population: JFAM study report 3. PLoS ONE, 2022, 17, e0264703.	1.1	0
702	A systematic review of clinical practice guidelines for myopic macular degeneration. Journal of Global Health, 2022, 12, 04026.	1.2	9
703	Masking of macular neovascular membranes by subretinal hyperreflective material on optical coherence tomography angiography. European Journal of Ophthalmology, 2022, , 112067212210853.	0.7	0
704	Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options. Clinical Ophthalmology, 2022, Volume 16, 917-933.	0.9	29
705	Long-term Retinal Morphology and Functional Associations in Treated Neovascular Age-Related Macular Degeneration. Ophthalmology Retina, 2022, 6, 664-675.	1.2	4
706	Correlation between Fundus Autofluorescence and En Face OCT Measurements of Geographic Atrophy. Ophthalmology Retina, 2022, 6, 676-683.	1.2	13
707	The value of handholding during intravitreal injections. Irish Journal of Medical Science, 2022, , .	0.8	0
708	Anti-angiogenic properties of rapamycin on human retinal pericytes in an in vitro model of neovascular AMD via inhibition of the mTOR pathway. BMC Ophthalmology, 2022, 22, 138.	0.6	5
709	Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema. Ophthalmology Retina, 2022, 6, 796-806.	1.2	11
710	Macrophage elastase (MMP12) critically contributes to the development of subretinal fibrosis. Journal of Neuroinflammation, 2022, 19, 78.	3.1	18
711	Short- and Long-Term Visual Outcomes in Patients Receiving Intravitreal Injections: The Impact of the Coronavirus 2019 Disease (COVID-19)â€"Related Lockdown. Journal of Clinical Medicine, 2022, 11, 2097.	1.0	7
712	Comparison of visual outcomes of polypoidal choroidal vasculopathy and typical neovascular ageâ€related macular degenerationâ€"up to 10â€‰years of followâ€up. Acta Ophthalmologica, 2022, 100, .	0.6	3
713	Long-term characteristics of exudative age-related macular degeneration in Japanese patients. PLoS ONE, 2021, 16, e0261320.	1.1	4

#	Article	IF	Citations
714	Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization. Biology, 2021, 10, 1328.	1.3	15
715	Long-Term Efficacy of a Treat-and-Extend Regimen with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: An Open-Label 12-Month Extension to the CANTREAT Study. Ophthalmologica, 2022, 245, 230-238.	1.0	0
716	Efficacy and Safety of Antivascular Endothelial Growth Factor (Anti-VEGF) in Treating Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Meta-analysis. Journal of Immunology Research, 2022, 2022, 1-11.	0.9	3
718	Trends, geographical variation and factors associated with the use of anti-VEGF intravitreal injections in Portugal (2013â€"2018): a retrospective analysis of administrative data. BMJ Open, 2022, 12, e055478.	0.8	4
720	Pharmacotherapy of Age-Related Macular Degeneration. , 2022, , 3619-3644.		1
721	IMPACT OF COVID-19 PANDEMIC LOCKDOWNS ON VISUAL ACUITY OF PATIENTS WITH NEOVASCULAR AMD. Retina, 2022, 42, 1529-1535.	1.0	0
722	Analysis of the Long-term Visual Outcomes of ForeseeHome Remote Telemonitoring. Ophthalmology Retina, 2022, 6, 922-929.	1.2	6
723	Adherence to the Mediterranean-Style Eating Pattern and Macular Degeneration: A Systematic Review of Observational Studies. Nutrients, 2022, 14, 2028.	1.7	15
724	nAMD: optimization of patient care and patient-oriented information with the help of an internet-based survey. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 3241-3253.	1.0	1
725	The Role of Retinal Plasticity in the Formation of Irreversible Retinal Deformations in Age-Related Macular Degeneration. Current Eye Research, 2022, , 1-7.	0.7	0
726	IL-33 enhances Jagged1 mediated NOTCH1 intracellular domain (NICD) deubiquitination and pathological angiogenesis in proliferative retinopathy. Communications Biology, 2022, 5, 479.	2.0	6
727	The negative impact of COVID-19 pandemic on age-related macular degeneration patients treated with intravitreal bevacizumab injections. International Ophthalmology, 2022, 42, 3387-3395.	0.6	3
728	Patterns of treatment discontinuation in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Indian Journal of Ophthalmology, 2022, 70, 2065.	0.5	4
729	Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. Science Translational Medicine, 2022, 14, .	5.8	20
732	A proteogenomic signature of age-related macular degeneration in blood. Nature Communications, 2022, 13, .	5.8	14
733	Towards the Development of Longer and More Efficacious Therapies for Wet and Dry Age-related Macular Degeneration. , 2022, 16, 30.		0
734	15 years of anti-VEGF treatment for nAMD: success or failure or something in between?. Eye, 2022, 36, 2232-2233.	1.1	8
736	Study of the Level of Pro- and Antiangiogenic Growth Factors in Vitreous Fluid in Neovascular Age-Related Macular Degeneration on the Background of Treatment. Oftalmologiya, 2022, 19, 368-377.	0.2	0

#	Article	IF	Citations
737	The impact of retinal fluid tolerance on the outcomes of neovascular age-related macular degeneration treated using aflibercept: A real-world study. PLoS ONE, 2022, 17, e0271999.	1.1	2
738	Ethnic differences on long term outcomes of polypoidal choroidal vasculopathy after predominantly bevacizumab monotherapy. BMC Ophthalmology, 2022, 22, .	0.6	0
739	Recent Advances in Age-Related Macular Degeneration Therapies. Molecules, 2022, 27, 5089.	1.7	23
740	A Real-World, Multicenter, 6-Month Prospective Study in Greece of the Effectiveness and Safety of Ranibizumab in Patients with Age-Related Macular Degeneration Who Have Inadequately Responded to Aflibercept: The â€œELEVATEâ€•Study. Clinical Ophthalmology, 0, Volume 16, 2579-2593.	0.9	1
741	Properties of Cephalopod Skin Ommochromes to Inhibit Free Radicals, and the Maillard Reaction and Retino-Protective Mechanisms in Cellular Models Concerning Oxidative Stress, Angiogenesis, and Inflammation. Antioxidants, 2022, 11, 1574.	2.2	1
742	Animal Models of Choroidal Neovascularization: A Systematic Review. , 2022, 63, 11.		13
743	Placental growth factor stabilizes VEGF receptor-2 protein in retinal pigment epithelial cells by downregulating glycogen synthase kinase 3 activity. Journal of Biological Chemistry, 2022, 298, 102378.	1.6	1
745	Destructive inflammatory reaction after an autologous retinal pigment epithelium and choroid transplantation: no detection of an auto-immune response. Journal of Ophthalmic Inflammation and Infection, 2022, 12, .	1.2	1
747	Long-term persistence with aflibercept therapy among treatment-naÃ¯ve patients with exudative age-related macular degeneration in a universal health care system: a retrospective study. BMC Ophthalmology, 2022, 22, .	0.6	3
748	Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy. Drug Design, Development and Therapy, 0, Volume 16, 3395-3400.	2.0	15
749	Effectiveness of bevacizumab step therapy for neovascular age-related macular degeneration. Eye, 2023, 37, 1844-1849.	1.1	2
750	Long-term results (60 months) of anti-VEGF therapy of macular diseases in real clinical practice. Part 1. Rossiiskii Oftal'mologicheskii Zhurnal, 2022, 15, 11-17.	0.1	1
751	Review of Fibrosis in Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2023, 246, 192-222.	1.7	5
752	Single-Cell Transcriptome of Wet AMD Patient-Derived Endothelial Cells in Angiogenic Sprouting. International Journal of Molecular Sciences, 2022, 23, 12549.	1.8	1
753	Macular Atrophy Incidence, Progression, and Visual Acuity Effects in 5-Year Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmic Surgery Lasers and Imaging Retina, 2022, 53, 546-552.	0.4	0
754	Clinical Phenotypes of Patients with Neovascular Age-Related Macular Degeneration and Poor Response to Aflibercept Treatment. Oftalmologiya, 2022, 19, 647-657.	0.2	0
755	Combination of AIBP, apoA-I, and Aflibercept Overcomes Anti-VEGF Resistance in Neovascular AMD by Inhibiting Arteriolar Choroidal Neovascularization. , 2022, 63, 2.		4
756	Changes on optical coherence tomography angiography and fluorescein angiography in eyes with neovascular age-related macular degeneration. International Journal of Ophthalmology, 2022, 15, 1837-1844.	0.5	0

#	Article	IF	Citations
757	Exploring the pathogenesis of age-related macular degeneration: A review of the interplay between retinal pigment epithelium dysfunction and the innate immune system. Frontiers in Neuroscience, 0, 16, .	1.4	18
758	Utilization of ferulic acid in Aspergillus niger requires the transcription factor FarA and a newly identified Far-like protein (FarD) that lacks the canonical Zn(II)2Cys6 domain. Frontiers in Fungal Biology, 0, 3, .	0.9	1
759	LONG-TERM TREATMENT OUTCOMES AFTER BEVACIZUMAB THERAPY FOR MACULAR NEOVASCULARIZATION IN WHITE PATIENTS WITH HIGH MYOPIA. Retina, 2023, 43, 444-453.	1.0	4
760	Short-Term Effects of Brolucizumab in the Treatment of Wet Age-Related Macular Degeneration or Polypoidal Choroidopathy Refractory to Previous Anti-Vascular Endothelial Growth Factor Therapy. Medicina (Lithuania), 2022, 58, 1703.	0.8	1
762	Recent trends in anti-vascular endothelial growth factor intravitreal injections: a large claims database study in Japan. Japanese Journal of Ophthalmology, 2023, 67, 109-118.	0.9	6
763	Visual Acuity in Patients Requiring Intravitreal Injections: Short-Term and Long-Term Effects of Delay in Care. Journal of Vitreoretinal Diseases, 0, , 247412642211366.	0.2	0
764	Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy. BMC Ophthalmology, 2022, 22, .	0.6	3
765	Progress of iPS cell-based transplantation therapy for retinal diseases. Japanese Journal of Ophthalmology, 2023, 67, 119-128.	0.9	5
766	Biofuels as Economic Security for the Poor. , 2022, , 201-218.		1
767	Choroidal Neovascular Membranes in Retinal and Choroidal Tumors: Origins, Mechanisms, and Effects. International Journal of Molecular Sciences, 2023, 24, 1064.	1.8	3
768	Treatment Strategies for Chorioretinal Vascular Diseases: Advantages and Disadvantages of Individualised Therapy. European Medical Journal Diabetes, 0, , 91-98.	4.0	0
769	Do anti-VEGFs used in the ophthalmic clinic cause MÃ¼ller glial cell stress?. Clinics, 2023, 78, 100161.	0.6	0
770	Bruchâ€™s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration. Journal of Clinical Medicine, 2023, 12, 2870.	1.0	7
771	Interaction of High-Molecular Weight Fucoidan from Laminaria hyperborea with Natural Functions of the Retinal Pigment Epithelium. International Journal of Molecular Sciences, 2023, 24, 2232.	1.8	6
772	Seven-year outcome after 1-year fixed regimen of intravitreal aflibercept injections followed by pro re nata treatment for neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 0, , .	1.0	0
773	Effective treatment of retinal neovascular leakage with fusogenic porous silicon nanoparticles delivering VEGF-siRNA. Nanomedicine, 2022, 17, 2089-2108.	1.7	1
774	Antiangiogenic therapy for ocular diseases: Current status and challenges. , 2023, 2, .		2
775	Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. Journal of Translational Medicine, 2023, 21, .	1.8	10

#	Article	IF	Citations
776	Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration. Clinical Ophthalmology, 0, Volume 17, 657-665.	0.9	2
777	Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology, 2023, 130, 735-747.	2.5	7
778	Influence of Clinical and Genetic Factors on the Progression of Age-Related Macular Degeneration: A 3-Year Follow-Up. Journal of Clinical Medicine, 2023, 12, 1963.	1.0	0
779	Persistence of vascular empty sleeves in choroidal neovascularization after VEGF therapy in both animal models and humans. Graefe's Archive for Clinical and Experimental Ophthalmology, 0, , .	1.0	0
780	MMP9â€Responsive Graphene Oxide Quantum Dotâ€Based Nanoâ€inâ€Micro Drug Delivery System for Combinatorial Therapy of Choroidal Neovascularization. Small, 2023, 19, .	5.2	5
781	Long-Term Visual Outcomes in Neovascular Age-Related Macular Degeneration Eyes With Baseline Macular Atrophy on Anti-Vascular Endothelial Growth Factor Treatment. Ophthalmic Surgery Lasers and Imaging Retina, 2023, 54, 223-230.	0.4	0
782	Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration. BMC Ophthalmology, 2023, 23, .	0.6	1
783	METTL3-mediated m6A modification of HMGA2 mRNA promotes subretinal fibrosis and epithelialâ€“mesenchymal transition. Journal of Molecular Cell Biology, 2023, 15, .	1.5	6
784	Effects of acupuncture on age-related macular degeneration: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 2023, 18, e0283375.	1.1	1
785	Fibrosis in neovascular age-related macular degeneration: A review of definitions based on clinical imaging. Survey of Ophthalmology, 2023, 68, 835-848.	1.7	3
786	Ten-Year Incidence of Fibrosis and Risk Factors for Its Development in Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2023, 252, 170-181.	1.7	4
787	Anti-inflammatory properties of antiangiogenic fucoidan in retinal pigment epithelium cells. Heliyon, 2023, 9, e15202.	1.4	2
798	Stages, pathogenesis, clinical management and advancements in therapies of age-related macular degeneration. International Ophthalmology, 2023, 43, 3891-3909.	0.6	1
804	Decoding Race and Age-Related Macular Degeneration: GPR 143 Activity Is the Key. Advances in Experimental Medicine and Biology, 2023, , 43-47.	0.8	0
805	New Avenues of Delivery (Subretinal Gene Therapy, Port Delivery, Suprachoroidal). Current Practices in Ophthalmology, 2023, , 339-351.	0.1	0
844	Macular Degeneration, Geographic Atrophy, and Inherited Retinal Disorders. , 2023, , 351-396.		0
854	RPE und der vaskulÃre endotheliale WachstumsfaktorÂ(VEGF). , 2024, , 93-109.		0